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ABSTRACT

QUALITY OF CARE IN PATIENTS WITH CIRRHOSIS AND ASCITES, HEPATIC
ENCEPHALOPATHY OR SPONTANEOUS BACTERIAL PERITONITIS

By
Ankur Dashputre
August 2017

Thesis supervised by Dr. Jordan R. Covvey

Objective: To analyze concordance with evidence-based clinical care guidelines in real world
clinical practice in patients with cirrhosis and ascites, hepatic encephalopathy (HE), or
spontaneous bacterial peritonitis (SBP).
Methods: A retrospective cohort analysis of the UPMC EMR database (2009-2014) with access
to full outpatient and limited inpatient data was conducted to identify patients with cirrhosis and
ascites, HE or SBP. Data regarding patient demographics, clinical characteristics, laboratory
values and medication utilization were extracted. Analyses included examination of patient
demographic and clinical characteristics, change in disease severity (via MELDNa scoring) from
cirrhosis to complication development and outpatient/inpatient healthcare utilization patterns.
Additionally, concordance with investigator-designed quality care indicators adapted from
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AASLD guidelines and other sources were assessed to understand real world clinical care.
Patient- and physician- factors predicting concordance with pharmacotherapy recommendations
were assessed via the use of logistic regression models.
Results: The inclusion/exclusion criteria yielded 4,116 patients with liver cirrhosis and 986, 665
and 148 patients with ascites, HE, and SBP respectively. Concordance with quality indicators
ranged from 49.83% (recommended medication for HE) to 99.32% (MELD at SBP index). Body
mass index and physician type were the only predictors that predicted concordance within the
regression models for the selected indicators (prescription for recommended ascites and HE
medications). A significant increase in MELDNa was observed from cirrhosis to complication
index. No differences in healthcare utilization patterns were observed across complications.
Conclusions: Several opportunities for improvement in quality of care were noted. However,
factors assessed in this study revealed limited information regarding opportunities to improve
concordance to clinical guidance.
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CHAPTER 1: INTRODUCTION
Liver cirrhosis
Background
Cirrhosis is a chronic condition of the liver characterized by the development of scarred
tissue and subsequent reduced capacity of liver function.1 The liver is involved in multiple
tasks such as processing of nutrients and their distribution, protein production and regulation,
drug metabolism, removal of toxic waste, and bile production, which are affected by
cirrhosis.1,2 Common etiologies of cirrhosis include chronic alcohol abuse, viral infections
like chronic hepatitis B, C or D, nonalcoholic fatty liver disease, bile duct disease caused by
backing up of bile into the liver, autoimmune hepatitis and genetic diseases like
hemochromatosis, Wilson’s disease or glycogen storage disease.1,2 The progressive nature of
the disease eventually leads to downstream complications such as portal hypertension (PH),
esophageal varices, ascites, spontaneous bacterial peritonitis (SBP), gastrointestinal bleeding,
hepatic encephalopathy (HE), renal failure and hepatocellular carcinoma (HCC); all of these
complications are associated with increased morbidity and mortality.3 The associated 1-year
mortality is 1%, 3.4%, 20%, 57%, and 67% for compensated cirrhosis with no esophageal
varices, compensated cirrhosis with varices, decompensated cirrhosis with ascites,
decompensated cirrhosis with gastrointestinal bleeding, and infections and renal failure,
respectively.3 Cirrhosis and its complications also impair health-related quality of life
(HRQoL). Factors such as insomnia, anemia, pruritus, muscle spasms, clinically overt
fatigue, depression and anxiety, and the presence of complications such as ascites and HE are
known to affect HRQoL negatively.4-6
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Pathophysiology
Damage and destruction of liver tissue resulting from the aforementioned etiologies initiates
a healing process where healthy liver tissue is counterintuitively replaced by fibrous tissue.7
This process, called fibrogenesis, leads to liver fibrosis, which can progress to cirrhosis
depending on the underlying etiology, host factors and environmental factors.7 Cirrhosis is
accompanied by the distortion of the hepatic vasculature, which involves angiogenesis, or the
formation of new blood vessels. Cirrhosis can lead to major consequences such as impaired
hepatocytes, increased intrahepatic resistance and development of HCC.7 The hepatic
vascular alterations are accompanied by other circulatory abnormalities such as splanchnic
vasodilation, hypoperfusion of kidneys, water and salt retention, and increased cardiac
output.7 All these processes result in PH, which further develops into serious complications
such as ascites, SBP, HE which are associated with higher mortality as discussed
previously.3,7 Hepatocytes are responsible for carrying out major functions of the body such
as protein synthesis and storage, carbohydrate metabolism, lipid metabolism, detoxification
of endogenous and exogenous substances; therefore, hepatocyte impairment affects these
processes adversely.7,8 Particularly, low albumin levels lead to decrease in oncotic pressure
allowing leakage of fluid from the interstitial spaces into the peritoneal cavity. The
combination of low oncotic pressure with PH contributes towards the development of
ascites.9 As mentioned earlier, hepatocyte dysfunction affects protein production which has
an effect on creatinine levels (a marker of kidney function) and clotting factors (increasing
bleeding risk) indicating liver damage. Also, the affected detoxification process may lead to
increased ammonia levels, which is a contributing factor for HE.
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Signs, symptoms, diagnosis
Early stage cirrhosis is typically difficult to diagnose until decompensation occurs as the
symptoms are not profound.2,3 Initial symptoms experienced by patients are generally nonspecific such as fatigue, weakness, decreased appetite, weight loss, and nausea.1,2 More
specific symptoms include nevus araneus (spider angioma, i.e. spider-like blood vessels),
severe itching (due to elevated bilirubin), abdominal distention due to fluid accumulation
(ascites), edema in the feet, ankles or legs, and jaundice.1,2 These signs/symptoms can be
further used as a basis to conduct diagnostic testing for confirmation.
Diagnostic techniques for cirrhosis are multimodal. A medical/family history provides
information on potential past exposure to hepatitis viruses (most commonly B or C), as well
as personal history of alcoholism or genetic and other prognostic factors that may have
contributed to the disease development.1 Laboratory blood work assessing liver enzyme
levels for aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline
phosphatase (ALP) and gamma-glutamyl transpeptidase (GGT) are generally conducted.10
Elevated levels of AST and ALT are markers of acute liver death. However, as cirrhosis
progresses, these levels might not always be elevated due to fewer healthy hepatocytes
releasing these markers when injury occurs.10 Elevated ALP levels suggest blockage of the
bile ducts, and elevated GGT levels indicate use of alcohol or bile duct diseases.10 Similarly,
blood protein levels can also be informative, including serum bilirubin (Sbili), serum
creatinine (SCr), international normalized ratio (INR), and albumin.1,10 SBili tests the
bilirubin level in blood and elevated levels indicate potential liver disease.1,10 SCr is a
measure of kidney function and elevated levels indicate abnormal kidney function, though
this may be misleadingly low in patients with severe cirrhosis due to lack of creatinine
production by the liver.1,10 INR is a measure of blood clotting ability with elevated levels
suggesting longer time for blood clotting, resulting from a lack of production of clotting
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factors by the liver.1,10 Reduced levels of albumin is an indication of liver disease and can
lead to ascites and abnormal fluid retention in extremities due to a decreased oncotic pressure
within the circulatory system.1,10
Sbili, SCr and INR have continued importance to cirrhosis as they are useful indicators to
calculate the Model for End-Stage Liver Disease (MELD) score.1 The MELD score,
developed by Kamath et al11 is a measure of the disease severity and is used as a predictor of
3-month survival to prioritize patients for liver transplantation. The MELD score is calculated
as follows:
MELD score = (0.957*loge (SCr) + 0.378*loge (SBili) + 1.120*loge (INR) + (0.643)) *10

The Organ Procurement and Transplantation Network recently updated the MELD score in
January 2016, including serum sodium (SNa) in the equation. The MELDNa (updated score)
is calculated as follows:12
1. Calculation of the MELD:
MELD = (0.957*loge (SCr) + 0.378*loge (SBili) + 1.120*loge (INR) + (0.643)) *10

2. Calculation of corrected SNa for patients with a serum glucose > 120 mg/dl:13
Corrected serum sodium (CSNa) = SNa + {0.024*(serum glucose – 100)}

3. Calculation of the MELDNa using the following formula:14
MELDNa = MELD + 1.32*(137 – SNa/cSNa) – [0.033*MELD* (137 – SNa/cSNa)]

For both the scores, patients who have undergone dialysis twice in a week and have SCr > 4,
their SCr value is set at 4.15,16 Any laboratory value < 1 for SCr, Sbili and INR is set at 1.15,16
Limits for SNa or CSNa values are set between 125 Mmol/L and 137 Mmol/L, with extreme
values outside of this range adjusted accordingly.17 A higher score corresponds with
increased severity of disease and mortality. Table 1 provides information on
MELD/MELDNa score and associated mortality.
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Table 1. MELD/MELDNa score and associated 3-month mortality15

MELD/MELDNa Score

Mortality at 3 months
(% patient expected mortality)

≤9

1.9%

10-19
20-29
30-39
≥ 40

6.0%
19.6%
52.6%
71.3%

MELD = Model for End-Stage Liver Disease; MELDNa = Model for EndStage Liver Disease with Sodium
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Finally, imaging tests like ultrasound, computerized tomography (CT) scans, and magnetic
resonance imaging (MRI) are used to study the liver surface, and to determine the presence of
gastric varices and splenomegaly. Liver biopsy may be utilized to evaluate tissue for
diagnosing the presence of damage or disease.1

Epidemiology and economic burden
According to 1999-2010 National Health and Nutrition Examination Survey (NHANES)
data, the prevalence of liver cirrhosis in the United States (US) is estimated at 633,323 adults
(0.27%).18 The prevalence by age is bimodal in nature, peaking in the 4th/5th decade of life
and again after 75 years of age.18 Cirrhosis prevalence is higher in males and in non-Hispanic
African-Americans, and Mexican-Americans.18 The 2014 National Vital Statistics Reports
ranks chronic liver disease and cirrhosis as the 12th leading cause of death accounting for
38,170 deaths (1.5% of all deaths due to all causes) with an age-adjusted death rate of 10.4
per 100,000.19 The 2010 National Center for Health Statistics reported an estimated 101,000
short hospital stays associated with chronic liver disease and cirrhosis,20 and an estimated
635,000 ambulatory visits in patients with cirrhosis in 2009.12
The economic burden of chronic liver disease and cirrhosis (ICD-9-CM 571.xx) based on
national hospital inpatient data in 2014 is estimated at approximately $1.5 billion with
alcoholic cirrhosis of liver (approximately $717 million), cirrhosis of liver without mention
of alcohol (approximately $457 million), and acute alcoholic hepatitis (approximately $190
million) contributing to the majority inpatient costs.21 Chronic liver disease and cirrhosis
accounted for an estimated $2.5 billion in direct costs (drug costs and hospitalizations) and
$10.6 billion in indirect costs (loss of work productivity) in 2004.22
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Treatment and guidelines
Liver cirrhosis does not have a definitive medical cure outside of transplantation, however
treatments are available to delay disease progression, reduce liver damage and decrease or
manage complications.2 The American Association for the Study of Liver Diseases
(AASLD), an organization of scientists and health care professionals with expertise in liver
diseases, provides evidence-based guidelines with recommendations on preferred approaches
for diagnostic, therapeutic and preventive aspects of liver disease care with the goal of
preventing, curing, and managing symptoms of liver disease.23,24 Based on the target liver
condition, the committee provides specific recommendations to be followed by practitioners
in their daily practice. The following sections describe selected complications and published
AASLD management guidelines.

Complications
As discussed previously, as cirrhosis progresses it can lead to several downstream
complications, such as esophageal varices, ascites, SBP, gastrointestinal bleeding, HE, renal
failure and HCC which are associated with 1-year mortality as low as 1% to as high as
67%.2,3 The development of complication stems from the restricted blood flow from the
portal vein through the liver which develops into PH, indicated by a hepatic-vein pressure
gradient (HVPG) of greater than 5 mmHg.3 If left uncontrolled, it develops into clinically
significant PH (HVPG > 10 mmHg).3 This commonly results in gastroesophageal varices,
(characterized by dilation of vessels in the esophagus) and increased incidence of HCC.3 In
particular, a HVPG ≥ 12 mmHg is associated with an increased risk of variceal bleeding
which can be fatal if not treated urgently.3 PH, sodium retention, changes in circulatory
oncotic pressure, and splanchnic vasodilation (due to increased nitric oxide production) are
major contributors to the development of ascites, which is characterized by excess fluid in
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peritoneal cavity.3 Bacterial infection of this excess peritoneal fluid is called SBP.3 The
destruction of liver tissue limits the removal of toxic nitrogenous substances from the body
leading to HE (characterized by altered mental status, confusion, and potentially a coma).25
Figure 1 presents a simplified outline of the progression of cirrhosis. The focus of present
study will be on ascites, SBP, and HE and the following sections will provide details of these
selected complications.
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Figure 1. Basic schematic presentation of cirrhosis progression

Early liver cirrhosis

Portal hypertension
(HVPG > 5 mmHg)
Increased levels of
nitrogenous products
in the blood

Gastroesophageal varices (HVPG
> 10 mmHg; characterized by
dilation of vessels in the
esophagus)

Reduced effective
blood volume,
increased cardiac output
and water and sodium
retention

Hepatic encephalopathy
(altered mental condition)
Ascites (retention of excess
peritoneal fluid)

Spontaneous bacterial peritonitis
(bacterial infection of peritoneal
fluid)

Portal-systemic shunting resulting
from variceal bleeding (HVPG ≥ 12
mmHg)
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HVPG: Hepatic-vein
pressure gradient

Ascites
Ascites is the most common complication of cirrhosis, and develops as a result of fluid
accumulation in the peritoneal cavity due to increased portal pressure and changes in
circulatory oncotic pressure.3,26 As cirrhosis progresses, homeostatic activation of
vasoconstrictor and anti-natriuretic factors occurs to maintain the effective blood volume.3
This leads to water and salt retention and eventual fluid accumulation in the peritoneal cavity
due to increased portal pressure.3 Approximately 50% of patients with cirrhosis who do not
have HE or variceal hemorrhage (two of the most common other complications) develop
ascites over a period of 10 years.27 The 1-year and 5-year morality rates associated with
ascites is 15% and 44%, respectively, and it is the most common reason for complicationrelated hospital admissions among cirrhotic patients.27 Based on severity, ascites can be
classified as mild (not clinically evident, but diagnosable by ultrasound), moderate
(symmetrical distension of stomach) or severe (noticeable tense distension of stomach).28
Diagnosis is ascertained by several components. Physical examination focuses on checking
for bulging abdominal flanks due to accumulation of fluid and may include an ultrasound to
visualize the fluid.27 Finally, an abdominal paracentesis is utilized to extract abdominal
ascitic fluid to test for ascitic cell count, levels of albumin and total protein, and for the
presence of bacteria.27 Patient medical history may also be reviewed for additional cause of
ascites such as cancer, heart failure, severe renal disease, thyroid disease, and tuberculosis.27
The goals of ascites management within the AASLD guidelines are to (1) control ascites, (2)
prevent or relieve ascites symptoms such as dyspnea or abdominal pain and distension, and
(3) prevent development of SBP and hepatorenal syndrome (HRS).28 AASLD-recommended
pharmacological therapies include:27
1) Baclofen: For patients with alcohol dependence to reduce cravings. Administered
orally at 5 mg three times daily (tid) for 3 days and then titrated to 10 mg tid.
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2) Diuretics: To aid in removal of volume overload (primarily ascites) and sodium. Firstline initial combination of oral spironolactone (100 mg) and oral furosemide (40 mg)
administered in the morning is recommended to achieve rapid natriuresis and to
maintain normokalemia. Oral spironolactone as single therapy can be used in patients
with minimal fluid overload. Second-line diuretics include amiloride, triamterene,
metolazone, and hydrochlorothiazide.
In patients with ascites, the vasodilatory effect (reduced blood pressure) of nitric oxide is
mediated by endogenous vasoconstrictors such as vasopressin, angiotensin, and aldosterone.3
Therefore, AASLD recommends caution/avoidance in the use of angiotensin converting
enzyme inhibitors (ACEI) and angiotensin receptor blockers (ARB) in patients with ascites,
unless there is compelling indication, as these agents counteract diuretics.27 In patients with
refractory ascites (ascites that does not recede post use of therapeutic paracentesis, sodium
restriction and diuretics), the risks of beta blockers (BB) should also be carefully considered
due to their effects on blood pressure and potential for paracentesis-induced circulatory
dysfunction, though these medications are recommended in PH.27 Lastly, nonsteroidal antiinflammatory drugs (NSAID) should be avoided in ascites as they reduce urinary sodium
excretion and can induce azotemia.27 Lastly, AASLD states that proton pump inhibitors (PPI)
use has an increased association with SBP (due to changes in bacterial growth in the GI tract)
and its use should be restricted to indications where necessary.27
Non-pharmacological strategies for ascites management include restriction of dietary sodium
to 2000 mg/day in conjunction with diuretics, monitoring urine sodium and fluid restriction
in patients with hyponatremia.27 In patients with significant edema, weight loss (due to fluid
loss using diuretics) is recommended.27 On resolution of edema, weight loss (due to fluid
loss) of 0.5 kg/day is considered reasonable.27 Use of large volume paracentesis is
recommended for patients with refractory ascites.27
11

Spontaneous bacterial peritonitis
SBP results from bacterial infection of the ascitic fluid caused by translocation of bacteriainfected GI tract fluid. In patients with cirrhosis and ascites, there is an increased intestinal
mucosal permeability, as a result of which bacteria migrate from lymph nodes to blood and
eventually ascitic fluid.28 Prolonged bacteremia, compromised host defenses, intrahepatic
shunting of colonized blood and defective bactericidal activity within the ascitic fluid are
additional factors that may lead to SBP.29 The estimated incidence rate of at least one episode
of SBP is 10-15% over 1-year in patients with ascites.29 SBP is associated with 20% of inhospital mortality among cirrhotic patients.30 In patients surviving SBP hospitalization, the 1year and 5-year mortality is approximately 70% and 80%, respectively.29 The recurrence rate
of SBP is approximately 40-70% within the first year of successfully clearing an episode of
SBP using antibiotic therapy.29
SBP is diagnosed by the presence of elevated absolute polymorphonuclear leukocyte (PMN)
count of ≥ 250 cells/mm3 in the ascitic fluid without an evident intra-abdominal surgically
treatable source of infection.27 Prevention is initiated with the use of primary (before the first
episode) and secondary (after the first episode) prophylaxis agents. The goal of prophylaxis is
to prevent the development of SBP in patients who potentially are at risk, including those
with ascitic fluid having a total protein < 1.5 g/dl along with impaired renal function (SCr ≥
1.2 mg/dl, blood urea nitrogen (BUN) ≥ 25 mg/dl, or SNa ≤ 130 mEq/L) or liver failure.27,30
It is also recommended to provide prophylaxis for 7-10 days immediately post variceal
hemorrhage.27 Secondary prophylaxis is always recommended after a prior episode of SBP.
AASLD recommends the following pharmacological therapies for prophylaxis of SBP:
1) Primary prophylaxis:
a. Norfloxacin 400 mg daily or trimethoprim/sulfamethoxazole double-strength
(800/160 mg) once daily,27 or
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b. Ceftriaxone 1 gram daily intravenously for 7 days or norfloxacin 400 mg
twice daily dose for 7 days in patients with cirrhosis and GI hemorrhage.27
2) Secondary prophylaxis:
a. Norfloxacin 400 mg daily or trimethoprim/sulfamethoxazole double-strength
(800/160 mg) once daily,27 or
b. Ciprofloxacin 500 mg daily may be utilized as an alternative in combination
with trimethoprim/sulfamethoxazole double strength.27,30
In patients who develop SBP, AASLD recommends initiation of empiric treatment in patients
with PMN ≥ 250 cells/mm3 in ascitic fluid in a community-acquired setting who have not
recently received beta-lactam antibiotics.27 These patients should receive a third-generation
cephalosporin, preferably IV cefotaxime (2 grams every 8 hours).27 Patients with PMN ≥ 250
cells/mm3 in ascitic fluid in a nosocomial setting and/or who have recently received betalactam antibiotics should receive antibiotic therapy according to local susceptibility
patterns.27 Finally, patients with PMN ≤ 250 cells/mm3 in ascitic fluid and signs/symptoms of
infection (temperature > 100o F or abdominal pain or tenderness) should receive IV
cefotaxime 2 grams every 8 hours (or a similar cephalosporin) while awaiting results of
culture for SBP confirmation.27
Oral fluoroquinolones such as ciprofloxacin, levofloxacin, moxifloxacin may be used as an
effective alternative to cefotaxime in patients without vomiting, shock grade II or higher HE,
or SCr > 3 mg/dl.27 Patients with SCr > 1 mg/dl, BUN > 30 mg/dl or Sbili > 4 mg/dl, should
also receive albumin 1.5 g/kg of body weight within 6 hours of detection and 1 g/kg on day 3,
though some clinicians recommend this therapy in all patients being treated for SBP.27
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Hepatic encephalopathy
HE is a form of cognitive dysfunction caused by liver insufficiency and/or portosystemic
shunting (PSS), which eventually manifests into multiple neurological or psychiatric
abnormalities.31 Scarred liver tissue in cirrhosis is unable to effectively remove ammonia and
other nitrogenous waste from the body.32 These waste products build up in the body and are
transported through the blood to the brain adversely affecting neuronal conduction.32 HE is
associated with a 1-year mortality rate of 64%.3
HE is described in two forms: overt HE (OHE) and covert HE (CHE).31 Minimal HE (MHE)
is a type of CHE, with no clinical sign or cognitive changes that might indicate HE which
might be seen in Grade I HE (another type of MHE) or OHE.31 OHE is characterized by
varied neurological and psychiatric abnormalities such as lethargy, disorientation, obvious
personality change, inappropriate behavior, dyspraxia, asterixis, somnolence, confusion,
bizarre behavior and coma.31 MHE is characterized by normal mental and neurological status
but may present with a slight delay in coordination.31 Prevalence of OHE is 10-14% at time
of cirrhosis diagnosis, 16-21% in those with decompensated cirrhosis and 10-50% in patients
with a transjugular intrahepatic portosystemic shunt.31 Overall, 30-40% of patients with
cirrhosis develop OHE at some point during their clinical course.31 MHE develops in 20-80%
of patients with cirrhosis.31 The annual economic burden of HE-attributable hospitalization is
estimated to range from $1 billion to $7 billion.33
Diagnostic techniques used for HE in patients with the aforementioned symptoms include
clinical evaluation for signs suggestive of liver insufficiency and/or PSS in patients with no
other obvious cause of brain damage.31 Clinical scales (to analyze severity) such as the West
Haven criteria, as well as neuropsychological or neurophysiological tests (diagnose cognitive
dysfunction) are also used.31 Use of psychometric or neurophysiological tests such as
portosystemic encephalopathy syndrome test, critical flicker frequency test, continuous
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reaction time test, inhibitory control test, Stroop test, SCAN test, electroencephalography
may provide additional information.31 MRI and CT scans are used in general for first-time
HE and in case of clinical suspicion of other pathology for brain disease.31 Finally, laboratory
testing to assess levels of ammonia in the blood is commonly performed.31 However, this
testing alone does not add any diagnostic, staging or prognostic value. Diagnosis is made
purely by a combination of symptoms, laboratory values and lack of other possible causes.
The AASLD provides guidelines for treatment of OHE, however MHE does not have any
specific guidelines, as its presence is not completely obvious to detection through routine
clinical examination. The recommendations are as follows:31
1) Nonabsorbable disaccharides: Lactulose 25 mL every 1-2 hours is recommended until
at least two soft or loose stools per day are produced and titrated further to maintain
two or three bowel movements per day. Lactulose works by preventing absorption of
ammonia within the gut. It is utilized as treatment for OHE, but also for prevention of
recurrent episodes of HE after the first episode.
2) Rifaximin: Used as an add-on therapy or alternative therapy to lactulose to prevent
OHE recurrence in patients who have experienced one or more bouts of OHE while
on lactulose therapy.
3) Neomycin: Used as an alternative therapy (last line) as it inhibits glutaminase which
is responsible for ammonia generation.
Non-pharmacological treatments for HE include maintaining a daily energy intake of 35-40
kcal/kg of body weight and daily protein intake of 1.2-1.5 g/kg of body weight/day.31

Problem statement
Medical care for chronic disease generally involves the use of multiple diagnostic,
therapeutic and preventive measures. When available, evidence-based guidelines provide a
15

strong framework for practitioners to implement recommendations, which improves the
quality of care and establishes a strong evidence-based practice. However, it is not
uncommon to see deviations from these evidence-based guidelines in the real-world practice,
which adversely impacts clinical care resulting in increased morbidity and mortality.
AASLD provides evidence-based guidelines for management of ascites, SBP and HE. Use of
these guidelines by healthcare professionals can provide guidance to quality care, reduce
disease burden, and decrease associated high mortality rates of the condition.3,5,34 However,
there is a need to evaluate how well these guidelines are utilized in practice, and what patientand physician- related factors may predict quality of care against clinical guidance.
Identifying these opportunities for clinical improvement aims to advance disease
management and patient experience of cirrhosis care.

Hypothesis
The overall hypothesis of this study is that there is no deviance from AASLD guidelines for
the selected therapies and quality indicators for quality care in patients with cirrhosis who
develop ascites, SBP and HE.

Research questions
1. To describe the demographic and clinical characteristics of patients with liver cirrhosis
2. To evaluate the change in severity (MELDNa) from cirrhosis to development of ascites,
SBP and HE
3. To assess the healthcare utilization patterns of patients with documented ascites, HE
and SBP
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4. To assess concordance with selected AASLD guidelines, and quality indicators and
determine the relationship between patient- and physician- related factors that influence
concordance
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CHAPTER 2: LITERATURE REVIEW
The aim of the literature review was to identify studies assessing concordance of clinical care
to established/recommended care guidelines/quality indicators and quality of care in patients
with liver cirrhosis and/or ascites, SBP and HE.

Search strategy
A systematic literature search was conducted using the Preferred Reporting Items for
Systematic Reviews and Meta-Analyses (PRISMA) guidelines, which were modified as
PubMed was the only database used.35 Peer-reviewed publications were searched using
PubMed. The search strategy included the keywords and/or combinations extracted from
PubMed MeSH terms (Refer Table 2). Broader terms used to extract MeSH terms were
cirrhosis, alcoholic cirrhosis, ascites, peritonitis, hepatic encephalopathy, guideline
adherence, benchmarking, quality of healthcare, quality assurance, health care, quality
indicators, health care and standard of care. In addition to extracted keywords, quality of
care was also used.

Inclusion/exclusion criteria
The inclusion criteria were as follows:
1. Studies published between January 2000 – July 2016,
2. Studies in English language,
3. Studies conducted in US and non-US based settings

The exclusion criteria were as follows:
1. Literature reviews, randomized clinical trials, dissertations, commentaries, editorials,
summary reports and conference abstracts,
2. Not focused on quality of care/guideline compliance in cirrhosis ascites, SBP and HE.
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The PRISMA chart showing search strategy is shown in Figure 2.
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Table 2. MeSH terms extracted from PubMed for literature search
Cirrhosis

Complications

Cirrhosis
 Liver cirrhosis(es)
 Hepatic cirrhosis(es)
 Liver fibrosis(es)

Ascites
 Ascites

Alcoholic cirrhosis
 Alcoholic liver cirrhosis
 Alcoholic cirrhosis
 Alcoholic hepatic cirrhosis
Miscellaneous
 Cirrhosis(es)
 Cirrhotic

Quality of care/
Guideline adherence
Guideline adherence
 Policy compliance
 Protocol compliance
 Institutional adherence

SBP
 Peritonitis
HE
 Hepatic encephalopathy(ies)
 Portal-systemic
encephalopathy(ies)
 Portosystemic
encephalopathy(ies)
 Portal systemic
encephalopathy(ies)
 Hepatocerebral
encephalopathy(ies)
 Hepatic coma(s)
 Hepatic stupor(s)
 Fulminant hepatic failure with
cerebral edema

Quality of healthcare
 Quality improvement(s)
Quality assurance, health care
 Healthcare quality
assurance(s)
 Health care quality
assurance(s)
 Healthcare quality
assessment(s)
 Health care quality
assessment(s)
Quality indicators, health care
 Healthcare quality
indicator(s)
 Healthcare global trigger
tool
Benchmarking
 Best practice analysis
 Benchmark
 Benchmarks
 Healthcare benchmarking
 Health care benchmarking
Standard of Care
 Standard of care
 Care standard(s)
Miscellaneous
 Quality of care

HE: hepatic encephalopathy; SBP: spontaneous bacterial peritonitis
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Records identified through searching PubMed using
combination of extracted MeSH terms
(n=1,329)

Records screened
(n=1,329)

Records excluded
(n=1,303)

Full-text articles assessed for eligibility
(n=26)

Full-text articles excluded
(n=14)
 5 research letters and
commentaries
 2 reviews
 1 abstract
 3 on cirrhosis but with
specific focus on
hepatocellular carcinoma,
hemorrhage, gastrointestinal
bleeding
 1 on validity of quality
indicators
 1 on development of quality
indicators
 1 article in French

Eligibility

Screening

Identification

Figure 2. Modified PRISMA diagram for literature review

Included

Studies included in qualitative synthesis
(n=12)

Studies included in qualitative synthesis
(n=12)
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MeSH: medical subject headings

Table 3. Studies evaluating quality of care, guideline/quality indicator concordance
Study
(year)
Country
US-based
Sclair SN36
(2016)
US
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Tapper EB38
(2016)
US

Lim N39
(2015)
US

Aim
To study the
adherence to
cirrhosis-specific
QI

Cirrhosis/
Complication
Cirrhosis

To study the
effects of QIm
protocol on 30day readmission
of patients with
liver cirrhosis

HE, SBP

To study the
relationship
between physician
specialty and

HE, RA, SBP

Setting

Study Sample

Benchmark/ Quality
improvement/ Quality
of care

Study findings

Retrospective cohort
study of patients seen at 3
healthcare facilities
(Faculty practice:
University of Miami
Health System; Safetynet: Jackson Memorial
Hospital and VA: Miami
VA Medical Center)
between Oct 1 2010 Mar 31 2011
Prospective study at the
inpatient facility of Beth
Israel Deaconess Medical
Center between 2010 2013

≥18 years; ICD-9CM diagnosis
cirrhosis (571.2, and
571.5)

Adherence to 6/41 QI
developed by Kanwal F
et al (2010)37 for
cirrhosis

Adherence ranges for QI:
 Faculty practice: 30-66%
 Safety-net: 25-73%
 VA: 30-63%

 67.7% of admitted overt HE
patients had documentation of
use of rifaximin
 42% of patients with history or
index admission of SBP
received secondary antibiotic
prophylaxis
 Checklist and electronic phases
received 8738 and 8858 20 mL
of lactulose doses respectively
(vs 6209 doses in usual care)

Retrospective study of
electronic medical
records at inpatient visits
at University of Vermont

≥18 years; inpatient
discharge diagnosis
of ICD-9-CM 571.2,
571.5 and 571.6

Two phase QIm (handheld checklist and
electronic phase vs usual
care) targeted at: Use of
rifaximin for all patients
with HE; Adjusting
lactulose dose to mental
status using the
Richmond Agitation and
Sedation Scale; Timely
administration of correct
dose of antibiotics and
albumin; Maximizing
patients who received
primary and secondary
prophylaxis for SBP
3 practice-based QM
each for RA and SBP
from AASLD 2009/2012
guidelines. 3 practice-

n=242 total with
n=85 Faculty
Practice; n=81 Safety
Net; n=76 VA
All patients admitted
to liver unit
n=824 total

Quality of care criteria met:
 RA: 20/39 admissions
 HE: 56/83 admissions
 SBP: 11/33 admissions

inpatient quality
of care i.e.
adherence to
evidence-based
specialty society
practice guidelines

Ghaoui R40
(2015)
US

To study the
impact of
implementing
mandatory
gastroenterologist
consultation (MC)
on adherence to
QI and outcomes
compared to usual
care (UC)

Medical Center between
Jun 2009 - Jul 2013

Ascites, HE

To study the
adherence to
guidelines for
reducing the
albumin dose at
large-volume
paracentesis
(LVP)

≥18 years; patients
with suspected/
established ascites,
HE

based QM for HE from
PPACP

 Intensivists-managed patients
received significantly better
quality of care
 Gastroenterology consultation
was associated with a
significantly higher adherence
to quality indicators for HE but
not for other complications

8 and 2 inpatient QI for
ascites and HE
respectively developed
by Kanwal F et al
(2010)37

Post implementation of MC
intervention (vs UC):
Ascites:
 82.2% received diagnostic
paracentesis post admission (vs
39.9%)
 75% admissions with known
portal-hypertension related
ascites receiving paracentesis
had ascites cell count checked
(vs 14.4%,)
 66.4% with normal renal
function received proper
management (vs 30.6%)

n=303 total with UC
n=149; MC n=154

UC cohort: Jan 1, 2009 Dec 31, 2009; MC
cohort: Jun 1, 2011 - Jun
30, 2012
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Johnson
KB41
(2015)
US

Comparison of
prospective cohort with
MC intervention to
retrospective review of
UC managed patients at
Baystate Medical Center.

n=247 total

Ascites

Retrospective cohort
study of patients with
LVPs at Department of
Radiology, Massachusetts
General Hospital between
Jul 1, 2009 - Jan 31, 2014

Patients with
gastroenterologistdocumented cirrhosis
and have undergone
LVP at Department
of Radiology
n=935 total with preguideline (PrG)
(July 1, 2009 - Jun
30, 2011): n=288;

4-point LVP guidelines
established by
interdisciplinary group
of radiologists,
hepatologists and
transfusion medicine
specialist

HE:
 85.8% had better documented
search of etiologies leading to
HE (vs 53.6%)
PoG group: 36.3% of LVPs
performed in accordance to
guidelines
Adherent vs non-adherent:
 Volume of ascites removed
was statistically higher (5.6 vs
5.2; p<0.001)
 Albumin dose administered
(g/L of ascites) and cost per
LVP was significantly lower

post-guideline (PoG)
(Jul 1, 2009 - Jan 31,
2014): n=647
Ghaoui R42
(2014)
US

Desai AP43
(2014)
US
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Kanwal F44
(2012)
US

To study
adherence to QI in
patients admitted
with
decompensated
cirrhosis
To study the effect
of co-management
between
hospitalists and
hepatologists on
quality of care and
adherence to
management
guidelines for
Chronic Liver
Disease and SBP

To study quality
of ascites care
provided to
Veterans using
established QI

Ascites, HE

Retrospective cohort
study of patients admitted
to Baystate Medical
Center between Jan 1,
2009 - Dec 31, 2009

SBP

Retrospective chart
review of patients
admitted with CLD and
SBP at University of
Chicago Medical Center
between July 1, 2004 June 30, 2010

Ascites, SBP

Retrospective cohort
study using records from
administrative and
clinical database followed
by a structured implicit
review of patient medical
charts using data from
Veteran electronic

≥18 years; ICD-9CM diagnosis of
571.0-571.9, 572572.4 and 576.0
n=149 total
≥18 years;
Patients with ICD-9CM for peritonitis
(567.23, 567.0,
567.21, 567.29,
567.89, and 567.9)
and Current
Procedural
Terminology code for
paracentesis (49080)
n=56 total with
Conventional Model
group (CM) (July 1,
2004 - June 30,
2006): n=26; Comanagement group
(CoM) (July 1, 2006 June 30, 2010): n=30
Patients with ICD-9CM for cirrhosis
(571.2, 571.5, 571.6)
or related
complications (456.0,
456.1, 456.20,
456.21, 572.2, 572.3,
572.4, 572.8, 789.5)
in inpatient or

(7.4 vs 11.9; p<0.001 and
$1,824.20 vs $2,107.63;
p<0.001, respectively)
7 and 2 QI for patient
with ascites and HE
respectively developed
by Kanwal F et al
(2010)37

Adherence to QI ranges:
 Ascites: 14.4-76.9%
 HE: 53.6-95.4%

12 evidence-based
recommended quality of
care processes for SBP

 CoM group was found to be
significantly more adherent to
5/12 processes as compared to
CM group
 Adherence ranged from 17100%
 Quality care provided by CoM
group was better

Adherence to 8/41 QI
developed by Kanwal F
et al (2010)37

 Adherence ranged from 2289%
 Quality of ascites care was
higher in the VA facility with
academic affiliation compared
with those without such
affiliation

medical record system
between 2000 - 2007

outpatient encounters
n=774 total

Non-US -based
Le S45
To study effect of
(2016)
adherence to
Australia
ascites QI on
clinical outcomes
for patients
hospitalized for
new onset
cirrhotic ascites
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Thevenot
T46
(2013)
France

Morando F47
(2013)
Italy

To evaluate
antibiotic
prophylaxis
prescription
tendencies for
primary and
secondary
prophylaxis of
SBP
To evaluate
efficacy and
financial
sustainability of
healthcare model
in comparison to
standard care

Ascites

Retrospective cohort
study of patients seen
Monash Hospital between
Jan 2000 - Oct 2012

SBP

Prospective national
survey of hepatogastroenterology
practitioners in general
hospitals (GH) and
university hospitals (UH)
between Nov 2011 - Mar
2012

Ascites

Prospective cohort study
of outpatients discharged
from the General Hospital
of Padova between Jan
1,2011 - Jun 30, 2011

≥18 years; ICD-9CM diagnosis of
portal hypertension,
cirrhosis (571.2,
571.5, 571.6), other
ascites), paracentesis,
and other sequelae of
chronic liver disease
(572.8)
n=302 total
Hepatogastroenterologist
practitioners
n=389 total

≥18 years;
n=100 total with
care-management
check-up group n=40
(Group 1); standard
care n=60
(Group 2)

Adherence to 8/13 QI
developed by Kanwal F
et al (2010)37 for ascites

 Adherence ranged from 7092%
 2 QI were significantly
associated with lower relative
risk of 30-day readmission
 1 QI each was significantly
associated with lower and
higher relative risk of 90-day
mortality

EASL, AASLD

 94.8% practitioners prescribed
secondary prophylaxis for SBP
(93.5% of GH vs 98.1% of UH
practitioners)
 72.3% practitioners used
antibiotics for primary
prophylaxis of SBP (70.7% of
GH vs 76.4% of UH)

Team of consultant
Group 1 vs Group 2:
hepatologists, nurses and  Reduction of mortality rate in
clinicians involved in
patients with responsive ascites
providing improved care
(24.2%, p<0.05) and those
through implementing
with refractory ascites (20.1%,
various quality
p=NS)
improvement initiative
 Significantly lower percentage
of 30-day emergent
readmission to the hospital
(15.4 vs 15.4%; p<0.01)
 Significantly lower percentage
of emergency hospitalization

during 12-month follow-up
(46.2 vs 71.2%; p<0.025)
Gundling
F48
(2009)
Germany

To study
adherence to
nutrition specific
recommendations
by
gastroenterologists

Cirrhosis

Prospective survey of
gastroenterologists at
Bavarian Society of
Gastroenterology
between Jul 1, 2007 - Sep
1, 2007

Gastroenterologists
n = 239 total
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Questionnaire (in
addition to 9 nutrition
specific questions)
seeking information on
knowledge of recent
guidelines on enteral
nutrition (EN) and
estimated relevance of
such guidelines, if such
guidelines can be
realizable in daily
practice and whether
careful advising by
professional dieticians is
meant to be important
for patients with liver
cirrhosis

 56% familiar with guidelines
on EN in patients with chronic
liver disease
 92% believed that evidencebased guidelines are both
important and relevant for
everyday practice
 84% considered such
recommendations as realizable
in daily practice

AASLD: American Association for Study of Liver Diseases; EASL: European Association for Study of the Liver HE: hepatic encephalopathy; ICD-9-CM: International Classification of
Diseases, Ninth Revision, Clinical Modification; PPCACP: Practice Parameters Committee of the American College of Gastroenterology; RA: refractory ascites; SBP: spontaneous
bacterial peritonitis; QI: quality indicator; QIm: quality improvement; QM: quality measures; VA: Veterans Affairs

Results
Table 3 provides a summary of the studies regarding complications, setting, study sample,
benchmark/quality improvement/quality of care criteria and study findings. A total of 12
articles were identified based on the inclusion/exclusion criteria out of which 8 were
conducted in the US36,38-44 and 4 were international studies45-48 (1 each in Germany, Italy,
France and Australia). Ten studies looked at concordance to quality indicators
(QI)/guidelines whereas two studies focused on quality improvement. Ascites was the most
common complication studied (7/12 studies, 58.3%), followed by SBP (5/12 studies, 41.7%)
and HE (4/12 studies, 33.3%). For the purpose of the review the study findings are
categorized into two categories: Concordance with QI/guidelines and Quality improvement.

Concordance with QI/guidelines
Five of the 10 studies on concordance with QI/guidelines (4 US and 1 in Australia) used QI
established by Kanwal F et al37 Sclair SN et al36 retrospectively compared the concordance to
six QI in three hepatology clinics [University of Miami Health System (faculty practice),
Jackson Memorial Hospital (safety-net hospital), and Miami VA Medical Center VA)] in the
Miami Health District, USA) for patients with cirrhosis receiving care from faculty at the
University of Miami. The percentage concordance to QI ranged from 30-66% (safety-net
hospital), 25-73% (faculty practice) and 39-63% (VA). Patients at the safety-net hospital and
VA received statistically higher Hepatitis A/B vaccination and hepatocellular carcinoma
surveillance in comparison to faculty practice patients. However, receipt of screening
endoscopy and discussions on liver transplant were statistically higher in faculty practice as
compared to the other two. Multivariate analysis results showed that patients with >10
hepatologist visits had statistically higher odds of receiving Hepatitis B vaccination and liver
transplant discussion (OR: 3.31, 95% CI 1.21-9.02; p<0.05 and OR 2.98, 95% CI 1.08-8.17;
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p<0.05 respectively vs 1-3 hepatologist visits). Females were more likely to receive a
Hepatitis B vaccination (OR: 2.62, 95% CI 1.17-5.91; p<0.01), and African-American
patients were less likely to receive liver transplant discussion (OR: 0.36, 95% CI 0.13-1.0;
p<0.05).
Ghaoui R et al40 compared concordance to eight QI (for ascites) and two QI (for HE)
between patients managed by gastroenterologist (prospective) and patients managed by usual
care (retrospective). In the prospective phase, concordance with QI for ascites ranged from
60-97.6% and for HE was 85.8-94.7%. For the gastroenterology group in comparison to usual
care, following QI were better met: (1) ascites: receipt of diagnostic paracentesis for ascitesrelated admission (82.2 vs 39.9%; p<0.001), checking for ascites cell count for those
receiving paracentesis with a known portal hypertension-related ascites admission (75.8 vs
14.14%; p<0.001), use of sodium restriction and diuretics combination (66.4 vs 30.6%;
p<0.001) and (2) HE: empirical treatment (95.3 vs 94.7%), and better documentation of
search for underlying etiologies (85.8% vs 53.6%; p<0.001). In an earlier retrospective study,
Ghaoui R et al42 looked at concordance with 7 and 2 inpatient QI for ascites and HE,
respectively. The concordance with ascites QI ranged from 14.4-76.9% and for HE 53.695.4%. Kanwal F et al44 retrospectively identified concordance with QI at the VA for patients
with ascites and SBP using 8 QI. The concordance with QI ranged from 22.2-82.8%.
Multivariate regression results showed that patients with higher serum sodium (125-135
mEq/ml and >135 mEq/ml) had lower odds of receiving recommended care (OR: 0.72, 95%
CI 0.52-0.99 and 0.58, 95% CI 0.35-0.74 respectively vs serum sodium < 125 mEq/ml);
patients with albumin ≥ 3 mg/dl had lower odds of receiving recommended care (OR: 0.51,
95% CI 0.35-0.74) vs albumin ≤ 2.2 mg/dl); patients without comorbidities received
recommended care compared to patients with comorbidities (Deyo index 0 vs > 3; OR: 2.21,
95% CI 1.43-3.43); patients who saw a specialist received higher quality of ascites care than
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those who did not (OR:1.33, 95% CI 1.01-1.74); the VA facility with academic affiliation
provided better care compared to those without such affiliation (OR:1.73, 95% CI 1.29-2.35).
Le S et al45 studied the effect of concordance with QI on 30-day readmission and 90-day
mortality of patients with ascites. Concordance with eight of the selected QI ranged from 7092%. Patients who received an abdominal paracentesis within 30-days of ascites diagnosis
and those receiving abdominal paracentesis during index ascites admission had lower odds of
30-day readmission (OR: 0.41, 95% CI 0.22-0.41; p=0.004 and OR: 0.57, 95% CI 0.38-0.57;
p=0.006, respectively). Patients with normal renal function receiving diuretics within 30-days
of ascites diagnosis had lower odds of 90-day mortality (OR: 0.28, 95% CI 0.10-0.77;
p=0.01). Interestingly, patients receiving primary prophylaxis (with ascitic fluid protein < 1
g/dl and serum bilirubin > 2.5 mg/dl) within 3 to 30-days of the test result had higher odds of
90-day mortality (OR: 2.30, 95% CI 1.05-5.05; p=0.04).
Lim N et al39 studied the relationship between physician and inpatient quality of care, as
measured by concordance with evidence-based guidelines (AASLD and Practice Parameters
Committee of the American College of Gastroenterology) for refractory ascites, SBP and HE.
Quality of care criteria was met in 20/39 inpatient admissions for refractory ascites; 56/83
admissions for HE and 11/33 admissions for SBP. A significantly higher proportion of
intensivist-managed admissions, compared with those managed by hospitalists, met criteria
for concordance with quality care indicators for HE (100 vs 63%; p=0.03), but not for
refractory ascites or SBP. Gastroenterology consultation was obtained in a significantly
higher proportion of admissions that met quality care criteria (68.7% vs 54.0%; p=0.023).
Among hospitalist-managed admissions, gastroenterology consultation was associated with a
significantly higher concordance with quality indicators for HE (86.9% vs 52%, p=0.004)
only.
Specifically for SBP, not having a timely diagnostic paracentesis was associated with
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significantly increased median length of hospital stay (5 days vs 13 days; p=0.02).
Johnson KB et al41 assessed the effect of concordance with 4-point guideline for reducing
albumin dose at large-volume paracentesis (LVP). Of the total 647 LVPs performed, only
235 were in concordance with the guidelines. In comparison to the non-concordant LVPs,
concordant LVPs had a significantly higher volume of ascites removed (5.6 vs 5.2 L;
p<0.0001); significantly lower amount of albumin dose delivered (7.4 vs 11.9 g/L; p<0.0001)
and lower cost per LVP ($1,824.20 vs $2,107.63; p<0.0001).
Desai AP et al43 compared the concordance with12 evidence-based indicators for SBP
patients treated by co-management model team (hospitalist team and liver consult team)
versus conventional model team (house staff team and liver consult team). The concordance
ranged from 17-100% for the co-management model team and 22-100% for the conventional
model team. The co-management model team provided overall better care and significantly
better care for 5/12 measures. Co-management group had non-significant longer length of
stay (11 vs 6 days) and cost of hospital stay ($82,888 vs $41,518). Percentage of readmission
at 30-days was non-significantly higher for co-managed group (31 vs 17%). However,
percentage of in-hospital mortality and mortality rate at 30-days was non-significantly lower
(13 vs 27% and 0 vs 5% respectively).
Thevenot T et al46 prospectively studied French national prescribing patterns of practitioners
treating SBP. Results showed that 72.3% prescribed primary prophylaxis for SBP (76.4%
university hospital based and 70.7% primary hospital based) and 94.8% prescribed secondary
prophylaxis for SBP (98.1% university hospital based and 93.5% primary hospital based).
Second-generation quinolones were prescribed majorly for primary and secondary
prophylaxis. High frequency use (> 75%) of primary prophylaxis was significantly associated
with high frequency use of secondary prophylaxis (OR: 3.57, 95% CI 1.41-9.09; p=0.007).
High frequency use of secondary prophylaxis was significantly associated with high
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frequency use of primary prophylaxis (OR: 2.86, 95% CI 1.16-7.19; p=0.022). Overall, there
was high concordance with guidelines by the practitioners.
Gundling F et al48 studied concordance with European Society for Parenteral and Enteral
Nutrition (ESPEN) guidelines by gastroenterologists for patients with cirrhosis. Of the 239
responses, 56% responded that they were familiar with guidelines on enteral nutrition. 92%
believed that evidence-based guidelines are both important and relevant for everyday practice
and 84% considered such recommendations as realizable in daily practice. 85% answered that
careful dietary counseling by professional dieticians would be important for treatment. 42%
recommended their patients a protein-rich diet containing 1.2-1.5 g/kg body weight/day,
whereas 15% advised a low-protein diet containing less than 40 g of protein/day or just the
same amount of protein as recommended in patients without cirrhosis. 45% were aware of the
optimal daily energy intake of whereas 43% underestimated the amount of required daily
energy while 11% advised higher energy intake.

Quality Improvement (QIm)
Tapper EB et al38 performed a prospective study to assess the effect of a QIm protocol on 30day readmission for HE. A two-phase (hand-held checklist and electronic) QIm initiative
targeted at: (1) use of rifaximin for all patients with HE, (2) adjusting lactulose dose to
mental status using the Richmond Agitation and Sedation Scale (3) timely administration of
correct dose of antibiotics and albumin, and (4) maximizing patients who received primary
and secondary prophylaxis for SBP was implemented compared against usual care. Results
showed that 67.7% of patients admitted with overt HE had documentation of use of
rifaximin; 42% with history or index admission of SBP received secondary antibiotic
prophylaxis; checklist and electronic phases received 8,738 and 8,858 20 mL of lactulose
doses respectively (vs 6,209 doses in usual care). Among patients initially admitted with
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OHE, the proportion readmitted within 30-days was significantly lower in the electronic
phase (26.0%) compared with the checklist (44.7%; p<0.001) and control phases (48.9%;
p=0.002) respectively. The use of rifaximin for patients admitted for overt HE was associated
with lower odds of 30-day readmission (OR: 0.39, 95% CI 0.16-0.87; p=0.02). Patients with
SBP who received secondary prophylaxis had lower odds of 30-day readmission (OR: 0.40,
95% CI 0.21-0.75; p=0.004). There was no significant association for 90-day mortality.
Patients with OHE who received 6 cups or more of lactulose had lower odds of 30-day
readmission (OR: 28.8%, 95% CI 5.3-52.7%; p=0.02).
Morando F et al47 studied the efficacy and financial sustainability of care management group
(CM) comprising of consultant hepatologists, nurses and clinicians versus standard care (SC)
for outpatients with ascites. Patients with responsive ascites and refractory ascites in CM
group had reduced 12-month mortality rate (24.2%; p<0.05 and 20.1%, p=NS. respectively)
as compared to SC. Patients in CM group had significantly lower percentage of 30-day
emergent readmission to the hospital (15.4 vs 42.4%; p<0.01) and lower percentage of
emergency hospitalization during 12-month follow-up (46.2 vs 71.2%; p<0.025) as compared
to SC. Global costs for CM was significantly lower for as compared to SC ($1,479.19 vs
$2,816.13; p<0.05).

Gaps in the literature
Studies focused on assessing concordance with guidelines/QI showed that concordance
varied and there was no specific trend observed due to the different guidelines/QI being
assessed.36,39-46,48 Results showed that specialists (hepatologists, gastroenterologists,
collaborative groups) provided better quality of care and were more concordant with
guidelines.39,40,43,44,47,48 Better concordance/implementation of QIm was generally associated
with lower odds of 30-day readmission.38,45,47 However, Desai AP et al43 found higher odds
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of re-admission associated with quality care. For the outcome of mortality, better
concordance/implementation of QIm was associated with lower odds of 30-day mortality
(Desai AP et al43) and of 12-month mortality (Morando F et al47). However, Le S et al45
found higher odds of 90-mortality. Overall, there was no consistency in the guidelines/QI
used for assessment, though QI by Kanwal F et al37 were used the most. For US-based
studies, concordance with evidence-based guidelines such as AASLD was assessed in only
one study.39 Majority of the studies did not discuss patient-related factors associated with
guidelines/QI concordance, while physician factors were discussed in few.
The results of this literature analysis provide sufficient justification for the aims of the
present analysis to assess the patient- and physician-related factors associated with
concordance/deviance to AASLD guidelines and selected quality indicators using
retrospective EMR data.
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CHAPTER 3: METHODOLOGY
The main goal was to assess concordance with evidence-based care in real world practice and
thus EMR was used as the data source, as they provide an in-depth understanding of current
clinical care.

Data source
The study design is a retrospective cohort analysis using electronic medical records (EMR)
from a large academic-based healthcare organization, the University of Pittsburgh Medical
Center (UPMC). The organization includes more than 20 hospitals and 500 outpatient offices
providing healthcare across southwestern Pennsylvania. The UPMC network additionally has
an insurance division, which covers nearly 3 million members.49

UPMC EMR database
A data extraction was requested from the UPMC Center for Assistance in Research using
eRecord (CARe), which provides access requests for healthcare data within the UPMC
network.50 CARe works with researchers to review research protocols, provide programming
support and access to other resources. The UPMC EMR data held through CARe contains
both inpatient and outpatient data on patient demographics and clinical characteristics,
clinical diagnoses, healthcare utilization, laboratory tests and associated results and
prescribed medications, among other data. In coordination with a UPMC clinician (Dr
Nemecek, thesis committee member), a data request was created for both Epic (outpatient
data) and Cerner (inpatient) systems.
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Data protection
Data extracted from the UPMC network was based upon an Enterprise Master Person Index
(EMPI) identification for the organization. This was subsequently converted to a dummy
patient ID (Code) for the purposes of data manipulation. No patient identifiers were present
in the data to maintain patient confidentiality. The researchers involved in the study were
certified by the Collaborative Institutional Training Initiative (CITI). The study was carried in
compliance with The Health Insurance Portability and Accountability Act of 1996 (HIPAA).
The study was approved by institutional review boards at both Duquesne University and
UPMC.

Database structure
The EMR database extracted by UPMC CARe and provided to the study investigators was
organized into a relational database structure. Relational databases have different tables,
which contain multiple rows and columns. Columns represent specific data attributes that are
stored in the table. For example, the DEMOGRAPHICS table includes columns such as year
of birth, sex, race etc. Rows represent data that is specific to each observation. For example,
each row in DEMOGRAPHICS table represents associated information for each patient. A
primary key, or unique identifier, relates all the tables in the database to each other. The EMR
database organized from the data extract contained five related tables, with a dummy patient
ID (Code) serving as the primary key. The five tables in the database are as follows:
DEMOGRAPHICS, OFFICE VISITS, HOSPITAL VISITS, LABORATORY TESTS, and
MEDICATIONS. Figure 3 depicts the database structure.
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Figure 3. Extracted UPMC EMR database structure

DEMOGRAPHICS
- Year of birth
- Sex
- Race
- Ethnicity
LABORATORY TESTS
- Test name
- Result date
- Test value
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HOSPITAL VISITS
- Hospital visit date
- Type of visit (OP, IP, ER)
- Provider specialty
- Diagnosis code (ICD-9-CM)
- Diagnoses description

Patient ID
i.e. Code
(primary key)

ER: emergency room; ICD-9-CM: International Classification of Diseases,
Ninth Revision, Clinical Modification; IP: inpatient visit; OP: outpatient

OFFICE VISITS
- Office visit date
- Height
- Weight
- Provider specialty
- Primary diagnosis (ICD-9-CM)
- Other diagnoses (ICD-9-CM)

MEDICATIONS
- Name
- Ordering date
- Dose
- Dose unit
- Route
- Frequency
- Directions of use

Study sample
Identification of study sample involved a two-step process:
Step 1
Creation of the study sample began with a data extraction by programmers from UPMC
CARe. This step-involved isolation of patients from the UPMC database based on following
inclusion criteria:
1. At least 18 years of age
2. At least two International Classification of Diseases, Ninth Revision, Clinical
Modification (ICD-9-CM) outpatient visit coding for cirrhosis (571.2, 571.5, 571.6)
or ascites (789.59), spontaneous bacterial peritonitis (SBP) (567.23) or hepatic
encephalopathy (HE) (572.2)
3. Outpatient visits between January 1, 2009 and December 31, 2014
4. At least 365 days of total EMR activity
This step yielded an initial cohort size of n=7,824. Detailed data from outpatient and limited
data from inpatient files were extracted for patients within this cohort and delivered to the
study investigators.

Step 2
To suit the specific study goals, a secondary step of data refinement was conducted by the
investigators and comprised of the following inclusion criteria:
1. Age between 18 and 90 years
2. At least one ICD-9-CM coding for alcoholic cirrhosis (571.2) or non-alcoholic
cirrhosis (571.5) as a primary or secondary diagnostic code at an outpatient visit
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This step yielded a study sample of n= 4,116, which was further stratified into three groups
based on the type of cirrhosis coding recorded during patient office visits. As each patient
had multiple office visits, they were stratified into:
1. Alcoholic cirrhosis (Alc): ICD-9-CM 571.2 only
2. Non-alcoholic cirrhosis (N-Alc): ICD-9-CM 571.5 only
3. Undetermined (Und): ICD-9-CM: 571.2 and 571.5 both
Complications observed after the first diagnoses of cirrhosis i.e. cirrhosis index (explained
shortly) were used as a part of the analysis. A total of 986, 665, and 148 patients with ascites,
HE, and SBP were identified, respectively.
Sample selection is represented in Figure 4.
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Figure 4. Patient selection criteria for study cohort

Patient sample extracted by CARe using initial inclusion criteria (n=7,824)

Step 1

Step 2
Patients with no outpatient visits
(n=205)

Outpatient visits between January 1, 2009 and December 31, 2014 (n=7,619)

Patients with no
primary/secondary
cirrhosis coding
(n=2,025)

Patients with at least one ICD-9-CM coding for alcoholic (571.2) or non-alcoholic (571.5) cirrhosis as
a primary/secondary outpatient visit code (n=5,594)

Patients with < 365
days of data
(n=1,475)

Patients with data > 365 days of data (n=4,119)

Patients < 18 years
and > 90 years
(n=3)

Final cohort meeting inclusion/exclusion criteria (n=4,116)
Ascites (n=986)
HE (n=665)
SBP (n=148)

Alcoholic cirrhosis
(ICD-9-CM: 571.2)
(n=404)

Nonalcoholic cirrhosis
(ICD-9-CM: 571.5)
(n=3,284)
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Undetermined
(ICD-9-CM: 571.2/571.5)
(n=428)

Description of study variables

Index dates (cirrhosis, complications)
The cirrhosis index date was defined as the first appearance of a cirrhosis diagnosis ICD-9CM of 571.2 or 571.5 as a primary or a secondary diagnosis at an outpatient visit during the
study timeframe. Similarly, complication index dates were defined as the first appearance of
an ascites (789.59) or HE (572.2) diagnosis recorded up to 10 diagnoses codes (including
primary diagnoses) at an outpatient visit during the study timeframe. For SBP (567.23)
diagnoses recorded up to ten diagnoses codes including primary diagnoses at an inpatient
visit was used to define index date as this complication is most commonly diagnosed in the
inpatient setting. Complications with a complication index on or after cirrhosis index were
used as part of the analysis for this study. Each of these variables is noted in this text as
cirrhosis index date, ascites index date, HE index date or SBP index date.

Patient demographic variables
Patient related variables include age, sex, race, and ethnicity. The information was obtained
from the DEMOGRAPHICS table and obtained from data reported in outpatient records,
although not directly derived from the OFFICE VISITS table.

Age at cirrhosis/complication index date
Age at the cirrhosis index date was calculated as the difference between index date and year
of birth. The variable year of birth was originally available in the DEMOGRAPHICS table.
Age at cirrhosis index was reported in years and categorized as: 18-40 years, 41-60 years and
≥ 61 years. Age at the complication index date was calculated as the difference between
index date and year of birth. The variable year of birth was originally available in the
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DEMOGRAPHICS table. Age at complication index was reported in years and categorized
as: 18-40 years, 41-60 years and ≥ 61 years.

Sex
The variable sex was used as an indicator of sex of the patient.

Race
The variable was categorized as: Caucasian, African-American, Other (American Indian,
Chinese, Filipino, Indian, Korean, Other Asian, Other Pacific Islander), and Undetermined
(not reported).

Ethnicity
The variable was categorized as: non-Hispanic, Hispanic and Undetermined (not reported).

Patient clinical variables
Clinical variables included body mass index (BMI) at index date, common co-morbidities,
Model for End-Stage Liver Disease score/-Na (MELD and MELDNa) score, and Cirrhosisspecific Comorbidity index (CirCom) score. BMI, common comorbidities, CirCom was
derived from information available in the OFFICE VISITS table. MELD was derived from
the LABORATORY TESTS table.

BMI at cirrhosis/complication index date
BMI at the cirrhosis index date was calculated based on the height and weight reported at the
cirrhosis index date in the OFFICE VISITS table. Height reported in feet and inches was
converted to meters and weight reported in pounds was converted to kilograms. BMI was
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reported as kilograms/meters2 (kg/m2) in the following established categories:51 0-18.5 kg/m2
(underweight), 18.5-24.9 kg/m2 (normal), 25-29.9 kg/m2 (overweight), ≥ 30 kg/m2 (obese)
and Undetermined (where BMI could not be determined due to missing height, weight or
both). Cases where height was not available at the index date, the height recorded at previous
or following outpatient visit was considered for the calculation. Similarly, BMI at
complication index date was calculated and reported in following categories: 0-24.9 kg/m2
(Underweight/Normal), 25-29.9 kg/m2 (overweight), ≥ 30 kg/m2 (obese) and Undetermined
(where BMI could not be determined due to missing height, weight or both). BMI categories
at complication index were collapsed due to the smaller sample size of patients within the full
stratification.

Common co-morbidities
Presence of comorbidities was based on ICD-9-CM coding from the first visit for the patient
in the database through three months’ post-cirrhosis index date. Up to ten diagnoses codes
(ICD-9-CM) including primary diagnoses code were looked up to determine presence of the
comorbidity. The comorbidities included in this study were based on investigator selection of
interest and the comorbidities considered by Jepsen et al52 for developing the CirCom score.
The type of co-morbidities included and associated ICD-9-CM is reported in Table 4.
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Table 4. Common co-morbidities and their associated ICD-9-CM code
Co-morbidity
COPD
AMI
PAD
Epilepsy
Alcohol abuse
Substance use other than alcohol
Heart failure
Diabetes
Depression
Viral hepatitis
Bipolar
CKD
Non-metastatic and nonhematological cancer
Metastatic cancer
Hematological cancer

ICD 9-CM codes
490.xx – 492.xx
494.xx
496.xx
410.xx
443.9
345.xx
305.0x
304.xx
305.1x – 305.9x
428.xx
250.xx
296.2x – 296.3x
311.x
070.xx
296.0x
296.4x – 296.8x
585.xx
140.xx – 195.xx
199.xx
209.xx
230.xx – 239.xx
196.xx
197.xx
198.xx
200.xx – 208.xx

AMI = acute myocardial infarction; CKD = chronic kidney disease;
COPD = chronic obstructive pulmonary disease; ICD-9-CM =
International Classification of Diseases, Ninth Revision,
Clinical Modification; PAD = peripheral artery disease
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Cirrhosis-specific Comorbidity index
The CirCom score is a newly developed cirrhosis-specific scoring system, which measures
the burden and effect of comorbidities on mortality. The CirCom score was developed and
validated by Jepsen et al52 in three different Danish population-based cohorts. The CirCom
was replicated in this study and was modified based data availability. Table 5 provides a
comparison between the method used by Jepsen et al52 and the current study. The CirCom
score calculation schematic is given in Figure 5. The CirCom score was calculated at the
cirrhosis index date and was reported in the following established categories: 0, 1+0, 1+1,
3+0, 3+1, 5+0, 5+1, in line with the original publication.
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Table 5. Comparison of current study with Jepsen et al52 for CirCom scoring
Country
Aim
Study cohorts and
sample size

Jepsen, et al
Denmark
Develop and validate CirCom
score
3 cohorts:

Current study
USA
Replicate use of CirCom score in US
population
1 cohort:

Developmental: Danish patient
registry cohort (nationwide
alcoholic or unspecified cirrhosis):
n= 12,976

UPMC cohort (hospital-based
alcoholic and non-alcoholic
cirrhosis): n= 4,116

Validation cohort 1: Aarhus
(hospital-based alcoholic
cirrhosis): n= 419

Comorbidities

Validation cohort 2: DANVIR
(nationwide chronic hepatitis C):
n=4,656
Chronic obstructive pulmonary
disease; acute myocardial
infarction; peripheral artery
disease; epilepsy; substance abuse
other than alcoholism; heart
failure; non-metastatic or
hematological cancer; metastatic
cancer; chronic kidney disease

Chronic obstructive pulmonary
disease; acute myocardial infarction;
peripheral artery disease; epilepsy;
substance abuse other than
alcoholism; heart failure; nonmetastatic or hematological cancer;
metastatic cancer; chronic kidney
disease

Diagnoses codes
Healthcare visit type
Comorbidity data
available for score
calculation

ICD-10-CM
Outpatient and inpatient visits
5 years of comorbidity data before
cirrhosis diagnosis

ICD-9-CM
Outpatient visits
Variable timelines for comorbidity
data before cirrhosis index date for
study years 2009-2014

Timeline for inclusion
of comorbidity for
scoring

5 years prior to cirrhosis diagnosis

Any time prior to cirrhosis index
date and up to 3 months postcirrhosis index date

Definition of ‘active’
Status for comorbidity

Within 7 days prior to cirrhosis
diagnosis

Within 7 days prior to cirrhosis
index date and up to 3 months postcirrhosis index date

CirCom = Cirrhosis-specific Comorbidity index; DANVIR = Danish HCV cohort; ICD-9-CM = International
Classification of Diseases, Ninth Revision, Clinical Modification; UPMC = University of Pittsburgh Medical Center;
US = United States
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Figure 5. CirCom scoring algorithm adapted from Jepsen et al52

COPD or
AMI or
PAD or
Epilepsy or
Substance abuse except
alcoholism or
Heart failure or
Cancer or
CKD

‘Active’ AMI and/or

YES

Patient has ‘active’
metastatic cancer

NO

‘Active’ non-metastatic or
hematological cancer and/or

NO

‘Inactive’ metastatic cancer
and/or
CKD

NO

Patient has more than one of
the listed comorbidities

YES

NO

YES
YES

CirCom Score 1+1

CirCom Score 1+0
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CirCom Score 0

Patient has at least one of
the listed comorbidities

YES
CirCom Score 5+1

AMI: acute myocardial infarction;
CKD: chronic kidney disease;
COPD: chronic obstructive pulmonary
disease; PAD: peripheral artery disease

Patient has at least one of
the listed comorbidities

NO
CirCom Score 5+0

YES

CirCom Score 3+1

NO

CirCom Score 3+0

Incident/prevalent cases
Patients who had an index cirrhosis diagnosis within 180 days from first visit recorded in the
database were classified as prevalent cases whereas patients who had their cirrhosis index
visit after 180 days from first visit were classified as incident cases.

Model for End-Stage Liver Disease (MELD)
As mentioned earlier, the MELD score is calculated based on laboratory values from serum
SCr in mg/dl, Sbili in mg/dl and INR. The formula for calculating MELD is as follows:
MELD score = (0.957*loge (SCr) + 0.378*loge (SBili) + 1.120*loge (INR) + (0.643)*10

As mentioned earlier, for patients with SCr > 4, the SCr value was set at 4.0; any laboratory
value < 1 for SCr, Sbili, and INR was set at 1. Patients who had a diagnosis coding (within
the first 10 diagnosis codings at an outpatient visit) of ICD-9-CM of V45.11 (renal dialysis
status) or 585.6 (end-stage renal disease) up to three months prior to and post-cirrhosis index
date, and complication index date were assumed to have an active dialysis status and their
SCr value was set at 4. The MELD score was calculated based on laboratory values available
three months prior, post the cirrhosis index date, and complication index date. To account for
varied possible values in the wide/broad window period, the numerical mean of the
laboratory values within the time frame was calculated for each test. The score was reported
in the following established categories:11,15 ≤ 9, 10-19, 20-29, 30-39 and ≥ 40 and two
additional categories of Undetermined (score not calculated due to missing values) and
Missing (scores not calculated due to absence of test).
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Model for End-Stage Liver Disease with Sodium (MELDNa)
As discussed earlier, The Organ Procurement and Transplantation Network recently updated
the MELD score in January 2016, and now includes SNa. The MELDNa (updated score) is
calculated as follows:12
1. Calculation of the MELD:
MELD = (0.957*loge (SCr) + 0.378*loge (SBili) + 1.120*loge (INR) + (0.643)*10
2. Calculation of corrected SNa for patients with a serum glucose > 120 mg/dl:13
Corrected serum sodium (CSNa) = SNa + 0.024*(serum glucose – 100)
3. Calculation of the MELDNa using the following formula:14
MELDNa = MELD + 1.32*(137 – SNa/cSNa) – [0.033* O-MELD* (137 – SNa/cSNa)]

Similarly, to MELD, for patients with SCr > 4, the SCr value was set at 4.0; any laboratory
value < 1 for SCr, Sbili, and INR was set at 1. Limits for SNa or CSNa values are set
between 125 Mmol/L and 137 Mmol/L, with extreme values outside of this range adjusted
accordingly.17
Patients who had a diagnosis (within the first 10 diagnosis codings at an outpatient visit) of
ICD-9-CM of V45.11 (renal dialysis status) or 585.6 (end-stage renal disease) up to three
months prior, and post the cirrhosis index date, and complication index date were assumed to
have an active dialysis status and their SCr value was set at 4. The MELDNa score was
calculated based on laboratory values available three months prior, and post the cirrhosis
index date, and complication index date. To account for varied possible values in the
wide/broad window period, the numerical mean of the laboratory values within the time
frame was calculated for each test. The score was reported in the following established
categories:11,15 ≤ 9, 10-19, 20-29, 30-39 and ≥ 40 and two additional categories of
Undetermined (score not calculated due to missing values) and Missing (scores not calculated
due to absence of test).
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Healthcare utilization variables
Healthcare utilization was quantified for ascites, SBP and HE using the OFFICE VISITS
table for office-based visits and HOSPITAL VISITS table for hospital observation, inpatient
and emergency room hospital visits. Utilization was quantified in two ways: (1) following a
1-year period from the complication index date, and (2) overall utilization across entire EMR
record from the complication index date. Patients had to have at least one year of data to be
included in the utilization metric analyses. Healthcare utilization for each type of service was
reported as the total number of visits for each complication, mean (± SD) and median (range)
visits.

Medication utilization variables
Medication utilization was described for ascites, SBP and HE. Medication-related data was
extracted from the MEDICATIONS table. The AASLD guidelines recommend
outpatient/inpatient medications to be prescribed for ascites, SBP and HE.27,31 Data on
outpatient prescriptions within 30-days post index-date of each complication were analyzed
to identify following recommended therapies:


Ascites: 100 mg daily of spironolactone alone or 100/40 mg daily of spironolactone
and furosemide in combination.27 The number of patients receiving a prescription,
mean (± SD) and median (range) dose was reported.



SBP: Ciprofloxacin 500 mg daily or combination of ciprofloxacin and double strength
sulfamethoxazole/trimethoprim (800/160 mg) once daily or
sulfamethoxazole/trimethoprim (800/160 mg) alone once daily.27 The number of
patients receiving a prescription was reported. Records were also screened for
prescription for levofloxacin and moxifloxacin and number of patients receiving each
was reported.
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HE: Lactulose or lactulose and rifaximin combination.31 The number of patients
receiving a prescription, mean (± SD) and median (range) dose was reported.

Medication dose strength per unit of time was calculated based on prescribed dose and
frequency. For example, total daily doses of 100 mg (dose strength /unit of time) were
calculated as a function of prescribed dose (e.g. 50 mg) and frequency (e.g. twice daily) when
appropriate. In case of multiple prescriptions in the 30-days post-index period, the
prescription closest to the index date was reported.
In addition to recommended medications, records were also analyzed for the following nonrecommended and/or cautioned medication classes and the number of patients receiving that
class was reported:


Ascites: NSAID, ACEI, ARB and BB. PPI as a preventive measure.27



HE: Hypnotics (HYP), opioids (OP), benzodiazepines (BZ) and sedating antidepressants (AD).53

Concordance with quality care indicators
Concordance with a set of investigator-designed (adapted from AASLD27 and Kanwal et al37)
quality indicators (Table 6) was also assessed, based on a review of the guidelines and the
quality indicators found in the literature review. Quality indicators 1, and 4 to 9 were adapted
from AASLD and Kanwal et al, and 2 and 3 were investigator-designed as measure of good
clinical practice. Concordance with each indicator was reported as number and percentage of
eligible patients, to evaluate the proportion of patients receiving established components of
quality care.
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Table 6. Quality care indicators
#

Quality indicator

Rationale

1

MELD/MELDNa score available at
complication index date

MELD score indicates the severity of the disease and
prioritization for liver transplant

2

MELDNa score available at complication
index date

3

Weight recorded at each cirrhosis visit

MELDNa is recently updated MELD score which
indicates the severity of the disease and prioritization
for liver transplant
Weight loss may occur as the disease progresses, and
weight gain is utilized as a surrogate measure of ascites
which requires monitoring

4

Seen by gastroenterologist at any followup visit post index cirrhosis visit

As complex disease process, specialist care is good
clinical practice to ensure appropriate treatment

5

Primary antibiotic prophylaxis for SBP
used in qualified patients

AASLD recommends use for patients with
cirrhosis/ascites who have ascitic fluid protein < 1.5
g/dL along with impaired renal function (creatinine ≥
1.2, BUN ≥ 25 or serum Na ≤ 130) or liver failure
(Child score ≥ 9 and bilirubin ≥ 3)

6

Diuretic therapy within 30-days postascites diagnosis

AASLD recommends use of spironolactone alone or in
combination with furosemide for management of
ascites

7

Secondary antibiotic prophylaxis within
30-days post-SBP hospital admission

AASLD recommends antibiotic treatment for patients
surviving an initial episode of SBP

8

Treatment within 30-days post-HE
diagnosis

AASLD recommends use of lactulose alone or in
combination with rifaximin for symptomatic HE

9

Not on any non-recommended therapies
Ascites (NSAID/ACEI/ARB/BB)
HE (HYP/BZ/AD/OP)

Classes of medications which either have
contraindications or precautions for use in patients with
cirrhosis due to potential for worsening or complication
of the disease process. Use of PPI in ascites due to an
observed association with risk for SBP

Not prescribed PPI in ascites

# = Number; AASLD = American Association for the Study of Liver Diseases; ACEI = angiotensin converting enzyme
inhibitor; AD = antidepressant; ARB = angiotensin receptor blocker; BB = beta blocker; BUN = blood urea nitrogen;
BZ = benzodiazepine; HE = hepatic encephalopathy; ICD-9-CM = International Classification of Diseases, Ninth Edition,
Clinical Modification; HYP = hypnotic; MELD = Model of End-Stage Liver Disease; MELDNa = Model of End-Stage Liver
Disease with sodium; Na = sodium; NSAID = nonsteroidal anti-inflammatory; OP = opioid; PPI = proton pump inhibitor;
SBP = spontaneous bacterial peritonitis
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Data management and statistical analysis
Data management and analysis was performed using Statistical Analysis System 9.4 software
(SAS Institute; Cary, NC) and Microsoft SQL Server 2012/2014 (Microsoft; Redmond, WA).

Research questions

Research question 1: To describe the demographic and clinical characteristics of patients
with liver cirrhosis
Distribution of patient demographic and clinical characteristics at the cirrhosis index date was
evaluated and their difference was assessed using two-way contingency tables across the
three extracted cirrhosis etiology categories: alcoholic (Alc), non-alcoholic (N-Alc), and
undetermined (Und). Frequencies and column percentages were reported for categorical
variables. A post-hoc Bonferroni correction was used to analyze between-group differences
for patient characteristics; accordingly, the two-tailed p-value of 0.05 was adjusted to 0.0166
(p-value/number of comparison groups = 0.05/3). Demographic characteristics included age
at cirrhosis index date, sex, race and ethnicity. Clinical characteristics included BMI,
additional diagnoses of biliary cirrhosis, other cirrhosis related etiology, incident or prevalent
case type, common comorbidities, CirCom score, MELD, and MELDNa. One-way analysis
of variance (ANOVA) was used to compare across continuous variables.

Research question 2: To evaluate the change in severity (MELDNa) from cirrhosis to
development of ascites, SBP and HE
The index dates for cirrhosis and each complication were ascertained. One-way ANOVA
with a post-hoc Tukey’s test was used to describe the difference between the MELDNa
scores across the three cirrhosis groups for each complication. The change in MELDNa score
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for complete cases was assessed using paired t-test, supplemented by the non-parametric
equivalent sign test. A time window of 6 months between cirrhosis index date and
complication index date (observed any time after 6 months) was used to assess the change to
avoid any overlap of MELDNa scores.

Research question 3: To assess the healthcare utilization patterns for ascites, SBP, and HE
Healthcare utilization was quantified for office-based, hospital observation, inpatient,
emergency room visits for patients with ascites, HE and SBP. Patients with ≥ 365 days of
data post-complication index date and more than 1 visit post-complication index were
included in the analysis. Utilization for each type of service was reported as the total number
of visits by type of service for each complication and, mean (SD) and median (range) of
visits. Utilization was quantified in two ways: visits in the first 365 days’ post-complication
index and total visits, adjusted by follow-up time frame. Follow-up was reported as the mean
(SD) and median (range) of duration in days. One-way ANOVA with a post-hoc Tukey test
was used to assess difference in distribution across Alc, N-Alc, and Und. A non-parametric
Kruskal Wallis test was used to supplement the ANOVA. Independent samples t-test was
used to assess difference in utilization for office-based, hospital observation, inpatient,
emergency room visits between ascites and HE.

Research question 4: To assess concordance with selected AASLD guidelines, and quality
indicators and determine the relationship between patient- and physician- related factors that
influence concordance
Concordance with each quality care indicator was reported as number and percentage of
eligible patients meeting the indicator criteria. Medications prescribed for ascites, HE and
SBP 30-days post index visit were extracted and the percentage of patients receiving
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recommended medication, mean (SD), median (range) dose was reported. In addition, nonrecommended medications were also extracted. A multivariable logistic regression was used
to evaluate the association of demographic and clinical characteristics with the receipt of
following quality care indicators:
1. Receipt of diuretic therapy within 30-days post ascites index date (y/n) = β0 + β
Age(ascites_index) + β Gender + β Race + β BMIascites_index + β MELDNaascites_index + β
Physician Type + β No. of comorbidities(based on CirCom) + β Cirrhosis type
2. Receipt of treatment within 30-days post-HE index date (y/n) = β0 + β Age(HE_index) +
β Gender + β Race + β BMIHE_index + β MELDNaHE_index + β Physician Type + β No.
of comorbidities(based on CirCom) + β Cirrhosis type
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CHAPTER 4: RESULTS

A total of n = 4,116 patients were included in the final analysis. Depending on the research
question being addressed, sub-samples were utilized and are reported accordingly.

Research question 1: To describe the demographic and clinical characteristics of
patients with liver cirrhosis

Sample size
The total sample size extracted based on the inclusion/exclusion criteria was n = 4,116. The
demographic and clinical characteristics are listed in Table 7.

Patient demographic variables
A total of 404 (9.82%) patients had a recorded diagnosis for alcoholic cirrhosis, 3,284
(79.79%) had a diagnosis for non-alcoholic, and 428 (10.40%) were deemed undetermined.
The mean age for the sample was 58.33 years (standard deviation [SD]: 10.97 years). A total
of 40.69% of patients were above 60 years of age whereas patients aged 18-40 years old
accounted for only 5.03% of the sample. The sample had a slight majority of males (55.68%)
as compared to females (44.32%). Race was reported for 98.66% of the sample and
Caucasians (90.33%) formed the majority. Similarly, ethnicity was reported for 97.69% of
the sample, with non-Hispanics (97.27%) being the most commonly reported ethnicity.
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Table 7. Distribution of demographic and clinical variables (n=4,116)
Individual
characteristics

Alc, n (%)
(n=404)

N-Alc, n (%)
(n=3,284)

Und, n (%)
(n=428)

p-value

Age (at index)
18-40
41-60
> 60

26 (6.44)
282 (69.80)
96 (23.76)

157 (4.78)
1,663 (50.64)
1,464 (44.58)

24 (5.61)
289 (67.52)
115 (26.87)

54.3 (10.06)

59.3 (11.09)

54.71 (9.16)

271 (67.08)
133 (32.92)

1,724 (52.50)
1,560 (47.50)

297 (69.39)
131 (30.61)

386 (95.54)
15 (3.71)
0
3 (0.74)

2,937 (89.43)
285 (8.68)
14 (0.43)
48 (1.46)

395 (92.29)
28 (6.54)
1 (0.23)
4 (0.93)

0
395 (97.77)
9 (2.23)

17 (0.52)
3,190 (97.14)
77 (2.34)

0
419 (97.90)
9 (2.10)

0.493

8 (1.98)
106 (26.24)
135 (33.42)
138 (34.16)
17 (4.21)

39 ((1.19)
596 (18.15)
906 (27.59)
1,587 (48.33)
156 (4.75)

14 (3.27)
130 (30.37)
142 (33.18)
126 (29.44)
16 (3.74)

<0.0001

273 (67.57)
131 (32.43)

1,768 (53.84)
1,516 (46.16)

307 (71.73)
121 (28.27)

<0.0001

62 (15.35)
12 (2.97)

991 (30.18)
47 (1.43)

82 (19.16)
20 (4.67)

<0.0001
<0.0001

1 (0.25)
403 (99.75)

77 (2.34)
3,207 (97.66)

2 (0.47)
426 (99.53)

0.0010

34 (8.42)
70 (17.33)
21 (5.20)
44 (10.89)
18 (4.46)
15 (3.71)
4 (0.99)
9 (2.23)
2 (0.50)
4 (0.99)
0
0
0

624 (19.00)
342 (10.41)
210 (6.39)
311 (9.47)
159 (4.84)
148 (4.51)
113 (3.44)
43 (1.31)
39 (1.19)
18 (0.55)
21 (0.64)
17 (0.52)
6 (0.18)

34 (7.94)
65 (15.19)
13 (3.04)
32 (7.48)
13 (3.04)
10 (2.34)
3 (0.70)
6 (1.40)
2 (0.47)
3 (0.70)
1 (0.23)
1 (0.23)
0

<0.0001
<0.0001
0.017
0.23
0.243
0.095
0.0004
0.335
0.271 †
0.387 †
0.208 †
0.414 †
1.000 †

<0.0001
<0.0001 §

Mean (SD)
Gender
Male
Female
Race
Caucasian
African-American
Other
Undetermined
Ethnicity
Hispanic
non-Hispanic
Undetermined
BMI (at index)
Underweight
Normal
Overweight
Obese
Undetermined
Incident case
Yes
No
Other etiology
Viral hepatitis
Alcohol abuse
Biliary involvement
Yes
No
Common comorbidities
Diabetes
SA w/o alcohol
COPD
Depression
Chronic kidney disease
Non-met/non-hem cancer
Heart failure
Bipolar disorder
PAD
Epilepsy
Hematologic cancer
Metastatic cancer
AMI

<0.0001

0.0062

Alc = alcoholic cirrhosis; AMI = acute myocardial infarction; COPD = chronic obstructive pulmonary disease;
N-Alc = non-alcoholic cirrhosis, PAD = peripheral artery disease; SA = substance abuse; Und = undetermined.
† Fisher’s exact test used; § ANOVA used
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Age at cirrhosis index, sex and race significantly varied across the three groups. Patients
classified with non-alcoholic cirrhosis were older (59.3 [SD: 11.09] years) as compared to
patients who had alcoholic cirrhosis (54.3 [10.06] years) or undetermined cirrhosis (54.71
[9.16] years) (p<0.0001). Patients with alcoholic or undetermined cirrhosis had a higher
proportion of Caucasian and male patients, compared to those with non-alcoholic, which had
increased proportions of female and African-American patients.

Patient clinical variables
BMI at index, incident/prevalent case type, biliary involvement, and presence of
comorbidities such as COPD, substance abuse other than alcohol, heart failure and diabetes
significantly varied across the cirrhosis categories. Presence of other cirrhosis etiologies such
as viral hepatitis and alcohol abuse also showed significant variation of distribution. CirCom,
MELD and MELDNa distributions could not be compared across the groups due to low
frequencies (n<5) within the categories present.
BMI at index date was calculated for 95.41% of the sample based on the availability of height
and weight variables. From the total sample, 44.97% of the patients were obese (≥30 kg/m2),
28.74% were overweight (25-29.9 kg/m2), 20.21% had normal BMI (18.5-24.9 kg/m2) and
1.48% were underweight (0-18.5 kg/m2). While alcoholic and non-alcoholic cirrhosis patients
had a larger proportion of obese patients, patients classified with undetermined cirrhosis were
most commonly overweight. A total of 57.05% of the cirrhosis cases were incident cases,
with alcoholic and undetermined cirrhosis contributing higher proportions than nonalcoholic. Biliary involvement was very low with only 1.94% of the sample having a
diagnosis for the same; however, this was significantly more common among those with nonalcoholic cirrhosis. Etiologies of viral hepatitis and alcohol abuse were observed in 27.97%
and 1.91% of the total sample, respectively. Diabetes (16.81%) was the most commonly
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observed comorbidity, which was most commonly seen in non-alcoholic cirrhosis. Substance
abuse other than alcohol was most common among patients classified with alcoholic and
undetermined cirrhosis.
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Table 7 (cont). Distribution of demographic and clinical variables (n=4,116)
Individual
characteristics
CirCom
0
1+0
1+1
3+0
3+1
5+0
5+1
MELD (at index)
≤9
10-19
20-29
30-39
≥ 40
Undetermined
Missing
MELDNa (at index)
≤9
10-19
20-29
30-39
≥ 40
Undetermined
Missing

Alc, n (%)
(n=404)

N-Alc, n (%)
(n=3,284)

Und, n (%)
(n=428)

299 (74.01)
67 (16.58)
13 (3.22)
25 (6.19)
0
0
0

2,491 (75.85)
425 (12.94)
122 (3.71)
230 (7.00)
7 (0.21)
6 (0.18)
3 (0.09)

335 (78.27)
62 (14.49)
11 (2.57)
19 (4.44)
0
0
1 (0.23)

90 (22.28)
166 (41.09)
50 (12.38)
7 (1.73)
0
66 (16.34)
25 (6.19)

1,081 (32.92)
1,257 (38.28)
244 (7.43)
15 (0.46)
1 (0.03)
539 (16.41)
147 (4.48)

81 (18.93)
240 (56.07)
47 (10.98)
10 (2.34)
0
35 (8.18)
15 (3.50)

56 (13.86)
131 (32.43)
62 (15.35)
11 (2.72)
0
119 (29.46)
25 (6.19)

770 (23.45)
1,096 (33.37)
309 (9.41)
21 (0.64)
1 (0.03)
940 (28.62)
147 (4.48)

51 (11.92)
196 (45.79)
64 (14.95)
12 (2.80)
0
90 (21.03)
15 (3.50)

MELD = Model for End-Stage Liver disease; MELDNa = Model for End-Stage Liver disease
with Sodium; Missing =score not calculated due to absence of test; Undetermined = score not
calculated due to missing values
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CirCom score based on comorbidities recorded from first visit in the database to three
months’ post cirrhosis index was calculated for the extracted sample. Seventy-six percent of
the patients had a CirCom score of 0 and 13.45% had a score of 1+0, reflecting that 89.37%
of the sample had a lower comorbidity burden and associated mortality. Despite an inclusion
period of 3 months pre- and post-index date, MELDNa could not be calculated for 32.45%
(27.91% undetermined due to missing values for test; 4.54% missing due to absence of test)
of the sample. For those with available laboratory results, 34.46 % of the patients had a
MELDNa score between 10-19, and the mean MELDNa score for the entire sample was
13.59 (SD: 5.84). Similarly, for MELD, 20.10% (15.56% undetermined due to missing values
for test; 4.54% missing due to absence of test) of the sample did not have a score, 40.40% of
the sample had score between 10 and 19 and the mean MELD score for the sample was 12.47
(5.27).
Patients with alcoholic and undetermined cirrhosis had a higher proportion of patients in
MELDNa categories of 20-29 and 30-39 compared to those with non-alcoholic cirrhosis,
which had increased proportions of patients with MELDNa ≤ 9. Patients with undetermined
cirrhosis had a higher proportion of patients with MELDNa of 10-19 compared to both
alcoholic and non-alcoholic cirrhosis. No variation was observed for the CirCom score.

Research question 2: To evaluate the change in severity (MELDNa) from cirrhosis to
development of ascites, SBP and HE

Sample size
Ascites, HE and SBP were observed in a total of 986 (23.96%), 665 (16.16%) and 148
(3.60%) patients in the sample, respectively.
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Distribution and changes in MELDNa
Of the total patients for ascites, HE and SBP, MELDNa scores were available for 805
(81.64%), 538 (80.90%), and 145 (97.97%) patients, respectively (Table 8). For patients with
ascites, the mean MELDNa score was significantly higher for undetermined cirrhosis as
compared to non-alcoholic cirrhosis (p=0.0003), but not for patients classified with alcoholic
cirrhosis. Similarly, for patients with HE, the mean MELDNa score was significantly higher
for undetermined cirrhosis and alcoholic cirrhosis compared to patients classified with nonalcoholic cirrhosis (p<0.0001). For SBP patients, mean MELDNa was significantly higher for
patients classified with alcoholic cirrhosis as compared to non-alcoholic and undetermined
cirrhosis (p=0.0146).
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Table 8. Distribution of complications and mean MELDNa score
Complication

Alc (n=404)

N-Alc (n=3,284)

Und (n=428)

p-value
(ANOVA)

Ascites (n=805)
n (%)
Mean MELDNa (SD)

95 (23.51)
17.90 (6.46)

542 (16.50)
16.15 (5.79)

168 (39.25)
18.04 (6.38)

0.0003*

HE (n=538)
n (%)
Mean MELDNa (SD)

55 (13.61)
18.40 (6.34)

377 (11.47)
15.91 (5.89)

106 (24.76)
18.63 (6.61)

< 0.0001*

SBP (n=145)
n (%)
Mean MELDNa (SD)

16 (3.96)
25.88 (6.99)

96 (2.51)
21.45 (5.71)

33 (7.71)
20.72 (6.30)

0.0146*

Alc = alcoholic cirrhosis; ANOVA= Analysis of Variance; HE = hepatic encephalopathy; MELDNa = Model for
End-stage Liver Disease with Sodium; N-Alc = non-alcoholic cirrhosis; SBP = spontaneous bacterial peritonitis;
SD = standard deviation; Und = undetermined cirrhosis
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When assessing changes in mean MELDNa from cirrhosis index date to complication index
date for complete cases, there was a statistically significant increase in the mean MELDNa
from cirrhosis index date to each complication index date observed any time after 6 months
post cirrhosis index (Table 9). The mean change for MELDNa was highest for SBP patients,
followed by ascites and HE.
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Table 9. Changes in mean MELDNa from cirrhosis index to ascites, HE, and SBP index
Index
Cirrhosis
Ascites

Sample
size
220

Mean MELDNa at
index (SD)
13.59 (4.54)
17.04 (6.36)

Mean difference
(SD)

t statistic

p-value

3.455 (5.808)

-8.823

< 0.0001*

Cirrhosis
HE

211

14.23 (5.22)
16.44 (6.03)

2.213 (5.880)

-5.467

< 0.0001*

Cirrhosis
SBP

69

15.81 (6.12)
21.59 (5.80)

5.783 (7.040)

-6.823

< 0.0001*

HE = hepatic encephalopathy; MELDNa = Model for End-stage Liver Disease with Sodium; SBP = spontaneous
bacterial peritonitis; SD = standard deviation
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Similar results were found when assessing median MELDNa from cirrhosis index date to
each complication index date observed any time after 6 months’ post cirrhosis index (Table
10). Patients with SBP had the highest median MELDNa at 21 (compared to 15 at cirrhosis
index), while patients with ascites and HE had median MELDNa of 16 (compared to 13 at
cirrhosis index) (all changes p<0.0001).
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Table 10. Changes in median MELDNa from cirrhosis index to ascites, HE, and SBP index
Index
Cirrhosis
Ascites
Cirrhosis
HE
Cirrhosis
SBP

Sample
size
220
211
69

Median MELDNa
at index (range)
13 (6-33)
16 (7-36)
13 (6-34)
16 (6-36)
15 (7-32)
21 (9-36)

p-value
< 0.0001*
< 0.0001*
< 0.0001*

HE = hepatic encephalopathy; MELDNa = Model for End-stage Liver Disease
with Sodium; SBP = spontaneous bacterial peritonitis
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Research question 3: To assess the healthcare utilization patterns for ascites, SBP and
HE

Sample size
Ascites, HE and SBP were observed in a total of 986 (23.96%), 665 (16.16%) and 148
(3.60%) patients respectively.

Office-based utilization – 1-year follow-up
A total of 347 (35.91%) patients with ascites had utilization data available for 1-year followup from index for office-based visits (Table 11). Overall, patients with ascites had 1,161
visits with mean utilization of 3.34 (SD: 3.10) visits in the 1-year follow-up. The nonalcoholic cirrhosis group had highest numerical utilization, but there were no significant
differences seen among cirrhosis groups, via either the ANOVA or Kruskal-Wallis tests for
means and medians, respectively. A total of 205 (30.82%) patients with HE had utilization
data available for 1-year follow-up for office-based visits. Overall, patients with HE had 615
visits with mean utilization of 3.00 (1.41) visits in the 1-year follow-up. The undetermined
cirrhosis group had the highest utilization, but ultimately no significant difference was
observed among the cirrhosis groups. A total of 5 (3.55%) SBP patients had visits in a 1-year
period from their index hospitalization. They had overall 13 visits with mean utilization of
2.60 (0.54) with median (range) of 3 (2-3). An independent samples t-test comparing overall
utilization for ascites and HE showed that there was no significant difference in utilization
between the two complications (p=0.074).
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Table 11. Office-based visit utilization during 1-year post-ascites, HE, and SBP index
Complication

Ascites

HE

SBP

Stratification

Visits, n

Mean (SD)

Overall (n=347)

1,161

3.34 (3.10)

Alc (n=51)

164

3.21 (1.28)

Non-Alc (n=212)

720

3.39 (3.78)

Und (n=84)

277

3.29 (1.61)

Overall (n=205)

615

3.00 (1.41)

Alco (n=19)

58

3.05 (1.12)

Non-Alc (n=144)

424

2.94 (1.46)

Und (n=42)

133

3.16 (1.35)

Overall (n=5)

13

2.60 (0.54)

p-value,
ANOVA
KW
-

Median
(range)
3 (2-54)
3 (2-7)

0.9207
0.8078

3 (2-54)
3 (2-9)

-

3 (2-14)
3 (2-6)

0.6605
0.3424

2 (2-14)
3 (2-8)

-

3 (2-3)

ANOVA = Analysis of Variance; Alc = alcoholic cirrhosis; HE = hepatic encephalopathy; SBP = spontaneous
bacterial peritonitis; KW = Kruskal Wallis; Non-Alc = non-alcoholic cirrhosis; Und = undetermined cirrhosis
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Office-based utilization – overall follow-up
A total of 437 (44.32%) patients with ascites had utilization data available for overall followup from index for office-based visits (Table 12). Overall, patients with ascites had 2,163
visits with mean utilization of 4.94 (4.32) visits across 1,085 days of follow-up,
corresponding to 1.66 visits/year. The undetermined cirrhosis group had highest utilization,
but no significant difference in utilization was seen between the three cirrhosis groups. A
total of 277 (41.65%) patients with HE had utilization data available for overall follow-up
from index for office-based visits. Overall, patients with HE had 1,257 visits with mean
utilization was 4.53 (2.81) visits over 1,049 days of follow-up, corresponding to 1.58
visits/year. The undetermined cirrhosis group had most utilization, but no significant
differences were seen in comparison to other cirrhosis groups. A total of 10 (6.71%) SBP
patients had data available for overall follow-up from their index hospitalization with a total
of 35 visits and a mean of 3.50 (1.17) visits over 1,070 days of follow-up, at 1.19 visits/year.
An independent samples t-test comparing overall utilization for ascites and HE showed that
there was no significant difference in utilization between the two complications (p=0.1237).
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Table 12. Office-based visit utilization overall post-ascites, HE, and SBP index

Complication

Stratification

Visits,
n

Overall (n=437)

2,163

Alc (n=63)

300

Non-Alc (n=269)

1,308

Und (n=105)

555

Overall (n=277)

1,257

Alc (n=26)

115

Non-Alc (n=200)

878

Und (n=51)

264

Overall (n=10)

35

Ascites

HE

SBP

Mean
(SD),
Mean/year
4.97 (4.32)
1.66
4.76 (2.95)
1.5
4.86 (4.76)
1.68
5.28 (3.79)
1.74
4.53 (2.81)
1.58
4.42 (2.19)
1.40
4.43 (2.80)
1.60
5.17 (3.07)
1.64
3.50 (1.17)
1.19

p-value,
ANOVA
KW
-

0.657
0.223

-

0.200
0.099

-

Median
(range),
Median/
year
4 (2-57)
1.5
4 (2-15)
1.38
4 (2-57)
1.56
4 (2-22)
1.39
4 (2-17)
1.55
4 (2-10)
1.33
4 (2-17)
1.62
5 (2-16)
1.69
3 (2-5)
1.12

Follow-up in
days,
mean (SD)
Median
1,084.75 (531.97)
974
1,157.68 (565.35)
1,054
1,058.16 (534.24)
933
1,109 (504.69)
1,049
1,049.14 (510.52)
943
1151.62 (543.07)
1,098
1,010.63 (499.66)
898
1,147.94 (525.55)
1,081
1,070 (570.52)
975

ANOVA = Analysis of Variance; Alc = alcoholic cirrhosis; HE = hepatic encephalopathy; SBP = spontaneous bacterial
peritonitis; KW = Kruskal Wallis; Non-Alc = Non-alcoholic cirrhosis; Und = Undetermined cirrhosis
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Hospital Observation/emergency utilization – 1-year follow-up
A total of 26 (2.63%) patients with ascites had utilization data available for 1-year follow-up
from index for hospital observation visits with a total of 73 visits and overall mean utilization
of 2.80 (SD: 1.09) visits (Table 13). A total of 5 (0.75%) patients with HE had utilization
data available for 1-year follow-up for hospital observation visits with a total of 15 visits and
overall mean utilization of 3.00 (1.73) visits. A total of 16 (1.62%) patients with ascites had
utilization data available for 1-year follow-up from index for emergency visits. Overall
utilization was 62 visits with mean of 3.87 (3.18) visits. For HE, 5 (0.75%) patients had
utilization data available with a total of 12 visits and mean utilization of 2.40 (0.89) visits.
ANOVA and Kruskal-Wallis tests were not conducted on hospital observation or emergency
visits due to the small sample size, and no data for either utilization type was observed for
SBP patients.

71

Table 13. Hospital observation/emergency visit utilization during 1-year post-ascites and HE
index
Health service type,
Complication
Hospital observation

Visits, n

Mean (SD)

Median (range)

Ascites (n=26)

73

2.80 (1.09)

2.5 (2-6)

HE (n=5)

15

3.00 (1.73)

2 (2-6)

Ascites (n=16)

62

3.87 (3.18)

2 (2-13)

HE (n=5)

12

2.40 (0.89)

2 (2-4)

Emergency visits

HE = hepatic encephalopathy; SD = standard deviation

72

Hospital observation/emergency utilization – overall follow-up
A total of 44 (4.46%) patients with ascites had utilization data available for overall follow-up
from index for hospital observation visits (Table 14). Overall utilization was 146 visits with
mean utilization of 3.31 (3.26) visits over 1,164 days follow-up, corresponding to 1.04
visits/year. For 10 (1.50%) patients with HE with available data, total utilization was 46 visits
with mean utilization of 4.60 (5.56) visits over 1,220 days, at 1.38 visits/year. A total of 24
(3.60%) patients with ascites had utilization data available for overall follow-up from index
for emergency visits, with total utilization of 99 and mean utilization of 4.12 (4.22) over 845
days, at 1.78 visits/year. A total of 6 (0.90%) patients with HE had available data, with
overall utilization of 22 visits and mean utilization of 3.66 (2.25) over 938 days follow-up,
corresponding to 1.42 visits/year. ANOVA and Kruskal-Wallis tests were not conducted on
hospital observation or emergency visits due to the small sample size. No hospital
observation visits were observed for SBP patients, while 2 (1.34%) patients had emergency
visits for overall follow-up.
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Table 14. Hospital observation/emergency visit utilization overall post-ascites and HE index
Health service type,
Complication

Visits, n

Mean (SD),
Mean/year

Median (range),
Median/year

Follow-up in days
Mean (SD)
Median

3.31 (3.26)
1.03
4.60 (5.56)
1.38

2 (2-22)
0.61
2.5 (2-20)
0.76

1,163.73 (541.53)
1,178
1,219.90 (592.77)
1,208

4.12 (4.22)
1.78
3.66 (2.25)
1.42

2 (2-20)
1.14
2.5 (2-7)
1.14

844.79 (479.56)
645
937.50 (532.84)
798.50

Hospital observation
Ascites (n=44)

146

HE (n=10)

46

Emergency visits
Ascites (n=24)

99

HE (n=6)

22

HE = hepatic encephalopathy; SD = standard deviation
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Inpatient utilization – - year follow-up
A total of 131 (13.28%) patients with ascites had utilization data available for 1-year followup from index for inpatient visits with a total of 575 visits at a mean (SD) of 4.39 (3.34) visits
(Table 15). The alcoholic cirrhosis group (n=14) had highest numerical utilization, but
results for ANOVA and Kruskal-Wallis showed that there was no significant difference in
utilization between the three groups. A total of 67 (10.07%) patients with HE had utilization
data available with overall 235 visits and mean of 3.50 (2.02) visits. The undetermined
cirrhosis group (n=16) group had most utilization, with the Kruskal-Wallis demonstrating a
significant difference in utilization. Independent samples t-test comparison between inpatient
visits for ascites and HE showed that ascites patients had a significantly higher number of
inpatient visits as compared to HE patients (p=0.0213). A total of 35 (23.48%) SBP patients
had inpatient visits in a 1-year period from their index hospitalization with total 77 visits and
mean of 2.20 (0.47) visits.
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Table 15. Inpatient visit utilization during 1-year post-ascites, HE, and SBP index
Complication

Ascites

HE

SBP

Stratification

Visits, n

Mean (SD)

Median
(range)

Overall (n=131)

575

4.39 (3.34)

3 (2-21)

Alcoholic (n=14)

69

4.92 (4.95)

3 (2-21)

Non-Alc (n=84)

349

4.16 (2.76)

3 (2-15)

Und (n=33)

157

4.75 (3.91)

4 (2-21)

Overall (n=67)

235

3.50 (2.02)

3 (2 -12)

Alcoholic (n=13)

41

3.15 (2.79)

2 (2-12)

Non-Alc (n=38)

123

3.23 (1.60)

3 (2-9)

Und (n=16)

71

4.43 (2.06)

4 (2-9)

Overall (n=35)

77

2.20 (0.47)

2 (2-4)

p-value,
ANOVA
KW

0.5710
0.8648

0.1072
0.0139*

-

Alc = alcoholic cirrhosis; ANOVA = Analysis of Variance; HE = hepatic encephalopathy; KW = Kruskal
Wallis; Non-Alc = non-alcoholic cirrhosis; SBP = spontaneous bacterial Peritonitis; Und = undetermined
cirrhosis
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Inpatient utilization – overall follow-up
A total of 160 (16.22%) patients with ascites had utilization data available for overall followup from index for inpatient visits with overall 926 visits and mean (SD) of 5.78 (4.72) over
1,006 days follow-up, corresponding to 2.1 visits/year (Table 16). The undetermined
cirrhosis group (n=38) group had most utilization, but no significant difference was detected.
A total of 87 (13.08%) patients with HE had utilization data available for overall follow-up
with total 414 visits at mean of 4.75 (4.09) visits over 913 days, at 1.90 visits/year. The
undetermined cirrhosis group (n=20) had the highest, albeit not significantly different,
utilization among groups. A total of 47 (31.54%) SBP patients had data available for overall
follow-up from their index hospitalization for inpatient visits with a total of 131 visits at 2.78
(1.45) visits over 1,072 days, for a total of 0.95 visits/year.

77

Table 16. Inpatient visit utilization overall post-ascites, HE, and SBP index

Complication

Stratification

Visits,
n

Overall (n=160)

926

Alcoholic (n=18)

104

Non-Alc (n=104)

570

Und (n=38)

252

Overall (n=87)

414

Alcoholic (n=13)

62

Non-Alc (n=54)

229

Und (n=20)

123

Overall (n=47)

131

Ascites

HE

SBP

Mean (SD),
Mean/year
5.78 (4.72)
2.1
5.77 (5.42)
2.04
5.48 (4.18)
1.92
6.63 (5.71)
2.68
4.75 (4.09)
1.90
4.76 (5.38)
1.45
4.24 (2.84)
1.73
6.15 (5.65)
2.9
2.78 (1.45)
0.95

Median
(range),
Median/
year
4 (2-33)
1.61
4 (2-24)
1.65
4 (2-25)
1.46
4 (2-33)
1.62
3 (2-27)
1.46
2 (2-19)
0.63
3 (2-15)
1.41
4 (2-27)
2.41
2 (2-7)
0.74

p-value,
ANOVA
KW
-

0.4412
0.2660

-

0.2057
0.1261

-

Follow-up in
days,
Mean (SD)
Median
1,005.95 (487.96)
907
1,031.67 (540.74)
885.50
1,039 (501.81)
1,000
903.31 (416.72)
799.50
913.48 (467.58)
750
1,201.62 (572.47)
1,155
895.33 (429.80)
777.50
775.20 (435.28)
605.50
1,072.36 (501.18)
988

Alc = alcoholic cirrhosis; ANOVA = Analysis of Variance; HE = hepatic encephalopathy; KW = Kruskal Wallis;
Non-Alc = non-alcoholic; cirrhosis; SBP = spontaneous bacterial peritonitis; Und = undetermined cirrhosis
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Research question 4: To assess concordance with selected AASLD guidelines, and
quality indicators and determine the relationship between patient- and physicianrelated factors that influence concordance

Sample size
Ascites, HE and SBP were observed in a total of 986 (23.96%), 665 (16.16%) and 148
(3.60%) patients, respectively.

Concordance with clinical care guidelines – ascites
Medication data was available for 892 (90.46%) patients with ascites. Of these, 514 (57.62%)
received recommended therapy of spironolactone alone or in combination with furosemide
within 30-days of index visit. Out of the 514 on recommended therapy, 118 (22.96%)
received spironolactone alone with a mean dose (SD) of 85.27 mg (50.49 mg). The remaining
396 (77.04%) received combination therapy with spironolactone/furosemide at a mean dosing
ratio of spironolactone to furosemide of 90.75 mg: 43.91 mg. A total of 284 (31.83%) of the
892 patients were receiving medications that would potentially require caution in prescribing
in this population, most commonly via the use of BB. Two-hundred and thirty-four patients
(26.23%) had a prescription for PPI. Table 17 describes the prescription pattern for ascites.
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Table 17. Medication prescription patterns for patients with ascites
Medication
Prescribed therapies (n=514)
Spironolactone/furosemide
Yes, n (%)
Mean dosing ratio (SD), mg
Median dosing ratio (range), mg

Metric

396 (77.04)
90.75 (48.49) / 43.91 (30.59)
100 (25-300) / 40 (10-240)

Spironolactone alone
Yes, n (%)
Mean (SD) dose/day, mg
Median dose/day, mg
Non-recommended/cautioned therapies (n=892)
NSAIDS*
Beta-blockers**
ACEI***
ARB****

118 (22.96)
85.27 (50.49)
100 (12.5-300)
65 (7.29)
230 (25.78)
26 (2.91)
18 (2.02)

Preventive for SBP (n=892)
PPI*****

234 (26.23%)

* includes aspirin, ibuprofen, naproxen, diclofenac, etodolac, meloxicam;
** includes propranolol, nadolol, carvedilol, labetalol, atenolol, bisoprolol-hydrochlorothiazide,
metoprolol succinate-hydrochlorothiazide, metoprolol succinate, metoprolol tartrate;
*** includes benazepril, enalapril maleate, lisinopril, lisinopril-hydrochlorothiazide, quinapril, quinaprilhydrochlorothiazide, ramipril;
**** includes valsartan, azilsartan, medoxomil-chlorthalidone, irbesartan, olmesartan, olmesartanhydrochlorothiazide;
***** includes omeprazole, esomeprazole, dexlansoprazole, lansoprazole, rabeprazole, pantoprazole
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Concordance with clinical care guidelines – hepatic encephalopathy
Medication data was available for 606 (91.12%) patients with HE. Of these, 302 (49.83%)
received recommended therapy of lactulose alone or in combination with rifaximin within
30-days of index visit. A total of 199 (65.90%) received lactulose alone with a mean dose
(SD) of 73.08 ml (46.48 ml). The remaining 103 (34.10%) received combination of lactulose
and rifaximin within 30-days of index visit. A total of 173 (28.55%) patients received nonrecommended medications such as HYP, BZ, AD, OP. Table 18 describes the prescription
pattern for HE.
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Table 18. Medication prescription patterns for patients with HE
Medication
Prescribed therapies (n=302)
Lactulose
Yes, n (%)
Mean (SD) dose, mL
Median (range) dose, mL

Metric

Lactulose/rifaximin

103 (34.10)

Non-recommended/cautioned therapies (n=606)
Opioids*
Hypnotics**
Benzodiazepines***
Antidepressants ****

124 (20.46)
12 (1.98)
45 (7.43)
32 (5.28)

199 (65.90)
73.08 (46.48)
60 (10-240)

* includes morphine, codeine, tramadol, hydrocodone, oxycodone, oxymorphone, hydromorphone,
fentanyl, methadone;
** includes zolpidem;
*** includes diazepam, lorazepam, temazepam, clonazepam, alprazolam;
**** includes trazodone, amitriptyline, doxepin, nortriptyline, mirtazapine
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Concordance with clinical care guidelines – spontaneous bacterial peritonitis
Medication data was available for 105 (70.94%) patients with SBP. Of these, 57 (54.29%)
received recommended secondary antibiotic prophylaxis of ciprofloxacin,
sulfamethoxazole/trimethoprim, moxifloxacin, norfloxacin or combination of ciprofloxacin
and sulfamethoxazole/trimethoprim within 30-days of index hospitalization. A total of 33
(57.89%) patients received some dosage of ciprofloxacin, while 20 (35.08%) received dose
combinations of sulfamethoxazole/trimethoprim. Table 19 describes the prescription pattern
for ascites.
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Table 19. Medication prescription patterns for patients with SBP
Medication
Prescribed therapies (n=57)
Norfloxacin 400 mg daily

Metric
1 (1.75)

Ciprofloxacin
500 mg weekly
500 mg daily
750 mg weekly
750 mg three times weekly
1000 mg daily
1500 mg daily

1 (1.75)
6 (10.52)
19 (33.33)
1 (1.75)
4 (7.01)
2 (3.50)

Moxifloxacin 400 mg daily

1 (1.75)

Sulfamethoxazole/trimethoprim
400/80 mg daily
400/80 mg three times weekly
800/160 mg daily

3 (5.26)
7 (12.28)
10 (17.54)

Ciprofloxacin and sulfamethoxazole/trimethoprim
750 mg weekly + 800/160 mg daily
750 mg weekly + 400/80 mg three times weekly

1 (1.75)
1 (1.75)
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Concordance with clinical quality care parameters
Varied concordance rates were observed across each investigator-assigned quality care
parameter (Table 20). Concordance ranged from 49.83% for indicator 8 (recommended HE
therapy) to 99.32% for indicator 1 (MELD for SBP). MELD/MELDNa scores were available
for almost all SBP patients at index (MELD: 99.32%; MELDNa: 97.97%), followed by
ascites (MELD: 89.45%; MELDNa: 81.64%) and HE (MELD: 88.87%; MELDNa: 80.90%).
Concordance with recommended therapy was highest for patients with ascites (57.62%),
followed by SBP (54.29%) and finally lowest for HE (49.83%). Non-recommended
medications were not prescribed to 71.45% and 68.16% of HE and ascites patients,
respectively. PPI was not prescribed to 73.77% of the eligible patients with ascites.
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Table 20. Concordance with quality indicators
Number
1

2
3
4
5
6
7
8

9

Indicator (Eligible n)

n (%)

MELD score available at complication index date
Ascites (n=986)
SBP (n=148)
HE (n=665)
MELDNa score available at complication index date
Ascites (n=986)
SBP (n=148)
HE (n=665)
Weight recorded at each visit for cirrhosis (n=4,116)
Seen by gastroenterologist at least once for all follow-up visit post index
cirrhosis visit (n=3,444)
Primary prophylaxis for SBP used in qualified patients (n=33)
Diuretic therapy within 30-days post-ascites diagnosis (n=892)
Secondary antibiotic prophylaxis within 30-days post-SBP hospital
discharge (n=105)
Treatment within 30-days post-HE diagnosis (n=606)
Not on any contraindicated/non-recommended therapies
Ascites (n=892)
HE (n=606)
Not prescribed PPI in ascites (n=892)

882 (89.45)
147 (99.32)
591 (88.87)
805 (81.64)
145 (97.97)
538 (80.90)
3,280 (79.69)
2,870 (83.33)
20 (60.61)
514 (57.62)
57 (54.29)
302 (49.83)
608 (68.16)
433 (71.45)
658 (73.77)

HE = hepatic encephalopathy; MELD = Model for End-Stage Liver Disease; MELDNa = Model for End-Stage Liver
Disease with Sodium; SBP = spontaneous bacterial peritonitis
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Patient- and physician-related factors influencing concordance – recommended diuretics
within 30-days of ascites index date

The results of standard multivariable logistic regression are shown in Table 21, with a total
of 712 patients included in the logistic regression model. No issues of multicollinearity were
identified, with all variance inflation factors < 5. Overweight patients had significantly
lower odds (OR: 0.559; 95% CI: 0.375-0.833) of receiving recommended diuretic therapy
as compared to patients who were underweight or had normal BMI. Non-gastroenterologist
or non-primary care physicians had significantly lower odds of prescribing the
recommended diuretic therapy as compared to primary care physicians (OR: 0.283; 95% CI:
0.134-0.598). MELDNa categories were collapsed to ≤ 9, 10-19 and ≥ 20 owing to the
sample size and distribution of scores.
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Table 21. Predictors of recommended diuretics within 30-days of ascites index date
Parameter

Reference

SE

0.8089

0.5303 2.3264

0.1272

-0.3339
-0.5996

0.3775 0.7824
0.3872 2.3984

0.3764
0.1215

0.716 (0.342 - 1.501)
0.549 (0.257 - 1.173)

0.00227

0.1620 0.0002

0.9888

1.002 (0.730 - 1.37)

-0.1509

0.3056 0.2439

0.6214

0.860 (0.472 - 1.565)

Underweight/
-0.5813
Normal
-0.0997

0.2036 8.1509
0.1994 0.2501

0.0043*
0.6170

0.559 (0.375 - 0.833)
0.905 (0.612 - 1.338)

0.2605 0.0871
0.2836 0.1383

0.7679
0.7099

1.080 (0.548 - 1.800)
0.900 (0.516 - 1.569)

Intercept
Age at ascites index
40-60
≥ 61
Gender
Male
Race
Other*
BMI at ascites index
Overweight
Obese
MELDNa at ascites
index
10-19
≥ 20
Physician Type
Gastroenterologist
Other
No. of comorbidities
1
>2
Type of cirrhosis
Non-Alcoholic
Undetermined

Wald
Pr >
Chi-Square ChiSq

B

18-40
Female
Caucasian

OR (95% CI)

≤9

0.0769
-0.1055

PCP

-0.00692 0.2034 0.0012
-1.2625 0.3817 10.9399

0.9729
0.0009*

0.993 (0.667 - 1.480)
0.283 (0.134 - 0.598)

0

-0.0665
-0.0611

0.1930 0.1188
0.3356 0.0331

0.7303
0.8556

0.936 (0.641 - 1.366)
0.941 (0.487 - 1.816)

Alcoholic

0.3193
0.2940

0.2498 1.6337
0.2824 1.0838

0.2012
0.2979

1.376 (0.843 - 2.246)
1.342 (0.771 - 2.334)

Logistic regression modelled for predictors of concordance with ascites therapy 30-day post index (n = 712)
Global null hypothesis for model, Likelihood Ratio test X2 =28.9577; Pr > ChiSq = 0.0106
B = parameter estimate, BMI = body mass index; CI = confidence interval; MELDNa = Model for End-Stage Liver Disease
with Sodium; OR = odds ratio; PCP = primary care physician; SE = standard error
* Race Other = African-Americans + Others
Number of comorbidities were calculated based on the presence of conditions specified by CirCom
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Patient- and physician-related factors influencing concordance – recommended HE therapy
within 30-days of HE index

The results of standard multivariable logistic regression are shown in Table 22. A total of
472 patients were analyzed by the model. No issues of multicollinearity were identified, with
all variance inflation factors < 5. The model indicated that obese patients had significantly
lower odds (OR: 0.431; 95% CI: 0.261-0.714) of receiving recommended HE therapy as
compared to patients with underweight or normal BMI. Non-gastroenterologist or nonprimary care physicians had significantly lower odds of prescribing the recommended HE
therapy as compared to primary care physicians (OR: 0.266; 95% CI: 0.087-0.813).
MELDNa categories were collapsed to ≤ 9, 10-19 and ≥ 20 owing to the sample size and
distribution of scores.
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Table 22. Predictors of recommended therapy within 30-days of HE index date
Parameter

Reference

Intercept

B

SE

Wald
Chi-Square

Pr >
ChiSq

0.0317

0.6476

0.0024

0.9610

0.5491
0.6190

0.4564
0.4631

1.4479
1.7862

0.2289
0.1814

1.732 (0.708 - 4.236)
1.857 (0.749 - 4.603)

0.1412

0.1973

0.5121

0.4742

1.152 (0.782 - 1.695)

OR (95% CI)

Age at HE index
41-60
≥ 61

18-40

Gender
Male

Female

Race
African-American

Caucasian

-0.3357

0.4167

0.6489

0.4205

0.715 (0.316 - 1.618)

BMI at HE index
Overweight
Obese

Underweight/
Normal

-0.1761
-0.8406

0.2603
0.2571

0.4578
10.6923

0.4987
0.0011*

0.839 (0.503 - 1.397)
0.431 (0.261 - 0.714)

MELDNa at HE
index
10-19
≥ 20

≤9

-0.1804
-0.3371

0.3173
0.3502

0.3232
0.9265

0.5697
0.3358

0.835 (0.448 - 1.555)
0.714 (0.359 - 1.418)

Physician Type
Gastroenterologist
Other

PCP

-0.2289
-1.3241

0.2454
0.5702

0.8698
5.3934

0.3510
0.0202*

0.795 (0.492 - 1.287)
0.266 (0.087 - 0.813)

No. of
comorbidities
1
>2

0

-0.1906
-0.2082

0.2323
0.3716

0.6727
0.3139

0.4121
0.5753

0.826 (0.524 - 1.303)
0.812 (0.392 - 1.682)

Type of cirrhosis
Non-alcoholic
Undetermined

Alcoholic

0.4395
-0.1279

0.3290
0.3746

1.7845
0.1166

0.1816
0.7327

1.552 (0.814 - 2.957)
0.880 (0.422 - 1.834)

Logistic regression modelled for predictors of concordance with HE therapy 30-day post index (n = 472)
Global null hypothesis for model, Likelihood Ratio test X2 =27.4656; Pr > ChiSq = 0.0167
B = parameter estimate, BMI = body mass index; CI = confidence interval; HE = hepatic encephalopathy; MELDNa =
Model for End-Stage Liver Disease with Sodium; OR = odds ratio; PCP = primary care physician, SE = standard error
Number of comorbidities were calculated based on the presence of conditions specified by CirCom
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CHAPTER 5: DISCUSSION

This chapter includes discussion of the study results, limitations of the analysis, and finally,
implications and opportunities for future research.

Liver cirrhosis and its complications are known to be associated with considerable mortality
and morbidity,3 and the prevalence of cirrhosis remains underestimated.18 Though no cure
exists, cirrhosis can be pharmacologically managed to delay the development of further
complications. The AASLD guidelines provide evidence-based practice recommendations for
diagnostic, therapeutic and preventive aspects of care for liver diseases. Derived from these
guidelines, clinicians and researchers have established indicators to measure achievement of
evidence-based delivery of quality care, such as those established by Kanwal et al37 A
number of subsequent studies have assessed concordance with quality care indicators for
ascites, HE and SBP as well as the impact of concordance on clinical outcomes.39,40,42-46,48
Patient- and/or physician-related factors predicting concordance with quality indicators were
assessed in only one study, which focused on ascites only.44 Thus, this study was conducted
to assess concordance with quality care using selected AASLD recommendations, quality
indicators by Kanwal et al37 and investigator developed quality indicators for ascites, HE and
SBP and assess patient- and physician-related factors predicting concordance with quality
care. The primary goal was to assess the concordance with established evidence-based quality
care parameters and/or guidelines and to further assess patient- and physician- factors that
influence concordance. Additionally, the study also described other preliminary analyses to
give a more complete picture of the care of patients with cirrhosis.
The first research question was to describe the sample characteristics that might potentially
affect concordance with and receipt of quality care, eventually influencing generalizability of

91

the results. Describing the demographic and clinical factors provided a survey of the patient
sample being analyzed and the potential applicability to other populations. The second
research question was to assess the change in disease severity via MELDNa across
development of different complications. Understanding the progression of cirrhosis with
clinical complications may provide a better idea of how to effectively manage patients. The
third research question focused on measuring office-based, inpatient, hospital observation
and emergency utilization for each complication. Receipt of poor quality of care can lead to
higher healthcare utilization and an overall increased burden on the patient. Healthcare
utilization patterns are thus an outcome of quality of care. This study however did not assess
utilization patterns as an outcome or predictor of quality care, but rather to understand the
burden of utilization for these complications. Finally, the final research questions focus
specifically on quality of care achievement and patient- and physician-related predictors.
The first objective of this study was to describe the overall sample based on the patient
demographic and clinical characteristics. Surprisingly, in this study 80% of the sample had a
diagnosis of non-alcoholic cirrhosis (cirrhosis without the mention of alcohol), whereas only
10% of the sample was diagnosed with alcoholic cirrhosis. Chronic alcoholism is the leading
cause of cirrhosis in the US and higher prevalence of alcoholic cirrhosis would be expected in
this sample.2 The National Institute of Alcohol Abuse and Alcoholism reports that of all
cirrhosis deaths (for 2013), 47.9% were attributable to alcohol.54 The Allegheny County
Health Survey reports 35% of the surveyed Allegheny County adults (≥ 18 years) selfreported binge drinking (defined as 5 or more drinks for males and 4 or more drinks for
females in the past 30-days) for the year 2015-2016, a statistic which fairly remains
unchanged when compared to year 2002 (34%) and years 2009-2010 (33%).55 Similarly, the
Substance Abuse and Mental Health Services Administration report on National Survey on
Drug Use and Health revealed that 25.6% of the surveyed adults (≥ 12 years) in the
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Pittsburgh Metropolitan Statistical Area self-reported binge drinking, as compared to the
national statistic of 23.2% (2005-2010).56 Though binge drinking does not necessarily
indicate alcoholism and further development of alcoholic cirrhosis, based on these statistics it
would be safe to assume that our sample had significantly low number of alcoholic cirrhosis
patients than expected. Ten percent of the patients were classified as having ‘Undetermined
cirrhosis’ (ICD-9-CM diagnosis for both alcoholic and non-alcoholic cirrhosis). Alcoholic
cirrhosis and non-alcoholic cirrhosis are two distinct exclusive classifications for identifying
the type of cirrhosis. It is surprising that 10% of the sample had a primary/secondary
diagnosis for both. This finding highlights the need for careful use of diagnosis codes to
classify patients based on underlying etiology as it may influence the nature of management
of such misclassified patients.
The estimates of age (mean age of 58.33 years), predominance of male gender (55.68%),
high BMI (30.5) and high prevalence of comorbid diabetes (16.81%) found in our study,
though not similar to the US national estimates for cirrhosis provided by Scaglione et al using
NHANES, were seen in a higher proportion for the mentioned characteristics.18 Scaglione et
al18 indicated a higher prevalence in non-Hispanic African-Americans (29.3%) and MexicanAmericans (34.3%). Our study was composed with a majority Caucasian population
(90.33%), which can be attributable to the demographics of the region of Pittsburgh (64.8%
non-Hispanic white, 2010 Census Bureau) served by the UPMC network.57 Based on age
distribution, male majority, number of patients with history of alcohol abuse and substance
abuse other than alcohol, it can be hypothesized that patients classified with undetermined
cirrhosis in this study might have alcoholic cirrhosis, but might have been misclassified as
those with non-alcoholic cirrhosis. This can be speculated based on the similarity of the
aforementioned patient characteristics. This study also utilized the CirCom score as an
indicator of cirrhosis-specific comorbidity burden, as compared to the more generic Charlson
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Comorbidity Index. Jepsen et al52 identified the comorbidities that impact survival in patients
with liver cirrhosis. Using a comorbidity score specific to cirrhosis would help understand the
burden in these patients much better than using a generic comorbidity index. Thus, the
current study tried to replicate this score in the study population being assessed to understand
their comorbidity burden. The original study developing the CirCom looked back 5 years
from first cirrhosis diagnosis to identify comorbidities, whereas our study had a variable
period before the index diagnosis as a result of EMR health system entry. Also, this study
used ICD-9-CM codes as compared to ICD-10 codes that were used in the original study, and
the definition of ‘active’ comorbidity as described in the present methods differed from that
of the original study. Though there were methodological variations, the distribution of
CirCom score observed was found to be similar to the original study.52 Approximately 76%
of the present sample was classified with CirCom score 0 (indicating no comorbidities), and
only 0.09% classified with CirCom score 5+1 (indicating high comorbidity burden). Current
study found a similar distribution trend as observed in the original study; as the score
increased from 0 to 5+1, the percentage of sample classified under each score decreased with
increasing severity. Based on the methodology used for the CirCom distribution it can be said
that this sample had a relatively low comorbidity burden, however an unequal time inclusion
period for comorbidities for each patient may have introduced some variation into the
distribution, namely a lower rate of comorbidity than the actual prevalence.
The MELD/MELDNa score is an indicator of disease severity and is used to prioritize
patients for liver transplant. It is calculated based on the laboratory testing for serum
creatinine, bilirubin, INR and sodium (for MELDNa only) which are not more than 48 hours
old.17 In this study, a wider time frame was utilized, ranging from 3 months prior to 3 months
post the cirrhosis/complication index date. This time frame was used to cast a wider net to
capture the severity of the patient using the retrospective design, as well as potential delays in
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laboratory tests in the outpatient setting. Though such a wide time frame was used,
MELD/MELDNa score could not be calculated for all the patients, with 20.10% and 32.46%
having data thereby making it difficult to calculate MELD and MELDNa respectively. This
could be potentially explained by several factors: (i) non-entry of values in the EMR, (ii) lab
test not ordered/performed, and (iii) the retrospective nature of study with no access to paper
medical charts.
Non-entry of lab values in the EMR for either or all the tests makes it impossible to calculate
the score as it is dependent on complete values. Though the records were identified based on
primary and secondary diagnosis for cirrhosis, there might have been an error in ordering lab
tests to calculate MELD/MELDNa. However, the error rate associated can be expected to be
low as a primary care physician or specialist would order these tests based on clinical
experience. Still, there is a chance that the necessary lab values were not ordered as a deficit
in good clinical care. It should be noted that the use of MELDNa was approved in January
2016, and thus not all physicians would have specifically recommended a test for serum
sodium as the study used EMR data from 2009-2014, leading to a MELDNa that could not be
calculated. However, as serum sodium is part of a basic metabolic panel commonly ordered
as a part of general clinical care, this cause would be less likely. Finally, records were
identified retrospectively using EMR, there is a possibility that the lab values obtained were
entered in paper medical charts for the patients but not in the EMR. The use of EMR within
the UPMC network is standard, but the degree to which supplemental paper is used in
individual offices is unknown.
The second study objective was to assess the change in disease severity via the MELDNa
from index date of the cirrhosis to the index date of each complication. In cirrhosis, liver
function is progressively affected due to disease pathophysiology. This affects the normal
functioning leading to elevated levels of creatinine, bilirubin, sodium and delayed clotting
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time, all of which are assessed with the MELDNa. A change in MELDNa score from
cirrhosis to complication index date was assessed to understand the change in severity and
extent of worsening of the disease over time. As a 3-month pre/post window from index date
of cirrhosis and complication was used, only those complications with an index date any time
6 months after the cirrhosis index were used to measure the change. The analysis showed that
there was a statistically significant increase in the severity from cirrhosis index to each of the
complication. The significant increase in severity indicates that severity can increase even
over a short period (6 months). As more complications develop, the increase in severity,
suggests that patients with cirrhosis are at an increased risk of mortality, as a higher severity
score corresponds with higher 3-month mortality and need for liver transplant.11,15 An
increase in MELDNa score as complications develop was seen, helping to verify the use of
this scoring system as a marker of disease severity.
The third study objective was to measure office-based, hospital observation, inpatient and
emergency utilization for the complications. Patients who had at least 365 days of data
available post-index and more than one visit were included and visits in a 1-year period from
index of complication as well as visits irrespective of follow-up period post-index was
measured. Office-based visits could be enumerated for ascites and HE only. Office visits for
patients with SBP could not be enumerated as these patients are generally seen in an inpatient
facility, as they are primarily diagnosed, managed and treated in such setting. For both
patients with ascites and HE, there was no significant difference in office-based utilization
between the three groups (alcoholic, non-alcoholic, undetermined) for both follow-up
periods. Based on the results, the underlying diagnosis may not necessarily impact the
severity of complication and eventually office-based utilization. Ascites patients had more
number of visits as compared to HE patients. This may have been observed as patients with
ascites might need paracentesis and more chronic care. However, mean office-based
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utilization between patients with ascites and HE did not significantly vary when compared
over 1-year as well as overall follow-up. Both the conditions require medical intervention due
to their complexity. Based on the results, it can be said that the burden of office-based visits
is not significantly different between patients with ascites and HE. Hospital observation and
emergency visits was observed in <5% of both ascites and HE patients for both the follow-up
period. Though, a small number of patients were analyzed, ascites patients had higher mean
emergency visits as compared to HE patients. Ascites patients may experience dyspnea and
abdominal pain due to the distension around the abdominal area and might require emergent
care for these conditions. HE patients had slightly more hospital observations as compared to
ascites. HE is episodic in nature and may require visits to the hospital so that the episodes are
managed effectively. Similarly, inpatient visits did not significantly differ amongst the
diagnosis groups in patients with ascites for both 1-year and overall follow-up period.
However, in patients with HE, a significant difference was observed on the Kruskal-Wallis
test (median/mean-rank) but not the ANOVA (mean visits) when comparing visits in 1-year
follow-up. Kruskal-Wallis test requires the distribution of dependent variable across
independent groups to have a similar shape to compare medians. The underlying distribution
of inpatient visits was not similar across the three groups; thus, it can be said that the mean
rank visit score differed but not the median visits. When comparing inpatient visits in HE
irrespective of follow-up, no significant difference was observed. For a 1-year follow-up,
ascites patients had significantly more inpatient visits than HE patients. This can be expected
as ascites patients may need inpatient services for the management of co-existing
complications such as SBP. No significant difference was observed in inpatient visits when
follow-up irrespective of time was considered. For SBP, 23.48% and 31.5% of patients had
inpatient visits in 1-year and overall follow-up, respectively. Differences across diagnosis
groups was not assessed due to the relatively small sample size and none to negligent office-
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based, hospital observation and emergency visits were observed. In general, comorbidity
burden may affect utilization patterns. However, 80% of our sample had low comorbidity
based on the CirCom score and thus the observed utilization patterns might not have been
influenced by the comorbid conditions.
The fourth and main objective of the study was to measure concordance with quality care
parameters and to assess patient- and physician- factors that influence concordance with these
quality care parameters. This question was divided into three parts: (i) concordance with
prescribing recommended medications for ascites, HE and SBP; (ii) concordance with
selected quality care parameters discussed in Table 6; and (iii) assessment of patient- and
physician-related factors that influence concordance with prescription of recommended
medications for ascites and HE. The timeline for assessing concordance to guideline varied
based on the QI. For QI 1 and 2, the concordance was based on MELD and MELDNa score
that could be reported at the complication index based on the 3-month pre/post inclusion
criteria for the contributing test values. QI 3 which assessed reporting of weight, the
concordance was based on the date of cirrhosis visit. QI 4 looked at follow-up visit with
gastroenterologist, and visits following cirrhosis index were assessed. QI 5 to 9 which
focused on prescriptions used a 30-day window from complication index as was used by
Kanwal et al.
For ascites management, outpatient prescribing of a combination of spironolactone and
furosemide or spironolactone alone is recommended as a first line therapy by AASLD, with a
recommended starting dose of 100 mg and 40 mg daily of spironolactone and furosemide
combination respectively, or 100 mg daily of spironolactone alone.27 The study results
revealed that only 58% of patients received either of the recommended diuretic therapies
within 30-days of outpatient visit. Of these patients 23% received spironolactone alone with a
mean (SD) daily dose of 85.27 mg (50.49) and 77% received combination therapy with a
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mean (SD) dosing ratio for spironolactone: furosemide of 90.75 (48.49) mg to 43.91 (30.59)
mg. Forty-two percent of patients did not receive or have any record of receiving any of the
assessed diuretic therapies within 30-days of outpatient visit.
The mean dose and mean dosing ratio for spironolactone and spironolactone: furosemide
combination respectively deviated slightly from the recommended doses. This may be
explained by the clinical judgment of the physician, who might have preferred a lower or
higher dose than recommended to be prescribed based on patient clinical factors such as
blood pressure, renal function or potassium abnormalities. It also may reflect a lower starting
dose and lack of upward titration over time. Additionally, as patients were identified with
ascites between 2009-2014 based on availability of the data, it is possible that the patients
might have had ascites before 2009 which is not captured and physician would have
prescribed (or adjusted) a lower or higher dose based on the prior knowledge of the response
and need of the patient for the dose of therapy.
Overall, the concordance with prescribing outpatient diuretic medications was lower
compared to earlier studies. Studies by Kanwal et al44 and Le et al45 assessing quality of care
in VA (n=774) and tertiary care hospital (n=302) population showed that concordance with
diuretic therapy was 82.8% and 86% respectively, broadly higher as compared to our study.
In our study, it is possible that the patients may have received the recommended therapy
more than 30-days after outpatient visit. In addition, it is possible that the prescription details
were not recorded in the EMR. Lack of appropriate diuretic therapy can have severe clinical
implications as they help in reducing the volume of ascitic fluid. Ascites itself is associated
with 1- and 5-year mortality of 15% and 44%, respectively; and SBP is further associated
with in-hospital 20% mortality.27,30
ARB, ACEI, NSAID and BB were prescribed to 2.02%, 2.91%, 7.29% and 25.78% of the
patients with ascites in the study. These medications are to be used with caution in patients
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with ascites, utilizing clinical judgment and consideration of comorbid conditions which may
warrant prescription. PH is a common cause leading to ascites and is managed by BB, thus
about a quarter of patients might have had a prescription for managing their PH.58-60 NSAID,
ARB, and ACEI interfere with renal perfusion and lead to reduce sodium excretion (due to
NSAID) and development of rapid renal failure (NSAID, ARB, and ACEI).27 Poor kidney
function will eventually lead to salt and water accumulation worsening the ascites and/or
progress to HRS which is associated with median survival time of 2 weeks and 6 months for
HRS type 1 and HRS type 2 respectively.61 This analysis is unable to state whether use of
these medications was completely clinically appropriate.
The AASLD mentions that use of PPI is associated with increased risk in patients with
cirrhosis and ascites. Though, there is no guideline around it, we assessed patients with
ascites with a prescription for PPI. Of the eligible 892 patients, 234 (26.23%) of the patients
had a PPI prescription. Though AASLD specifies restricting the use of PPI (citing only one
study) to only those conditions where needed, controversy exists around the association
between PPI use and risk of SBP.27,62 Multiple studies using retrospective, prospective
designs, systematic reviews and meta-analyses have shown conflicting results (positive as
well as negative association) and there is no conclusive evidence or consensus confirming a
causality to support a guideline on using caution while prescribing ascites patients with PPI
to reduce SBP risk.62-81 Though our study found over a quarter patients with ascites having a
prescription for PPI, it cannot be strongly said that deviation from quality care was observed,
due to the conflicting evidence. PPI may have been prescribed to these patients for other
existing conditions which were not analyzed as a part of this study.
Recommended therapies for HE were prescribed to 50% of patients, which was similarly
poor to prescribing for ascites. A total of 66% of those receiving recommended therapy were
prescribed lactulose; whereas the remaining 34% were prescribed lactulose and rifaximin in
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combination. Lactulose and lactulose with rifaximin as an add-on has been recommended by
the AASLD guidelines for HE management based on meta-analysis and clinical trial
data.31,82-86 HE is characterized by cognitive and motor dysfunctionality and considering that
AASLD recommends the aforementioned medications, the observed poor concordance is of
concern, particularly as the associated 1-year mortality rate is up to 64%.3 It is to be noted
that AASLD guidelines are mostly focused on management of OHE, and not CHE or MHE.
The guidelines recommend CHE/MHE treatment on a case-by-case basis, using the same
treatments as for OHE. We could not ascertain if the patient had OHE or CHE/MHE which
might have contributed to the observed concordance, as patients with MHE/CHE might not
have received the treatment. In addition, hypnotics, antidepressants, benzodiazepines and
opioids were prescribed to 1.98%, 5.28%, 7.43% and 20.46% of the eligible patients for HE
quality care parameter. Though not specifically mentioned in the AASLD guidelines,
literature supports avoidance of these medications in HE as they can cause cognitive
dysfunction or even worsen the condition and thus good clinical judgment would suggest that
these medications should be prescribed with care.53
Long-term outpatient antibiotics within 30-days of hospital discharge post-SBP is a
recommended secondary prophylactic strategy by Kanwal et al37 and AASLD (with no
specific mention of 30-day window). Secondary prophylaxis was prescribed to 54% of
patients, which was overall less than optimal, but lies between HE (lower) and ascites
(higher) concordance. Majority of patients (57.89%) were prescribed varied doses of
ciprofloxacin (with 57.57% receiving a 750 mg/weekly dose); followed by varied doses of
sulfamethoxazole/trimethoprim (35.08%). Thevenot et al46 in their study assessing
prescribing for GI bleeding and SBP, found that 94.8% of the practitioners prescribed
secondary prophylaxis over life (defined as resolution of ascites or until transplantation), a
significantly higher concordance as compared to our study. Le et al45 assessing quality care
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and its association with outcomes in hospitalized patients found 70% concordance rate for the
patients eligible for secondary prophylaxis. Kanwal et al44 in their study assessing quality of
care for ascites in VA population found that of the 30 eligible patients only 30% received
secondary prophylaxis. Overall, this study found less than desirable concordance to the
quality care parameter, lower than studies by Thevenot et al46, and Le et al45, but
comparatively better than Kanwal et al.44 Recurrence rate of SBP is approximately 40-70%
within the first year of successfully clearing an episode of SBP using antibiotic therapy.29 The
less than desirable concordance observed is a cause of concern as patients surviving SBP
hospitalization have an associated 1-year and 5-year mortality of approximately 70% and
80%.29
When identifying patients eligible for this SBP indicator, up to ten ICD-9-CM codes
including primary diagnoses for that hospitalization were used to identify SBP patients. There
is a possibility that patients who did not present with SBP as a primary condition for
hospitalization did not receive the recommended antibiotic prophylaxis. Due to retrospective
nature of this study it is difficult to assess if the non-prescribing is attributable to SBP not
being the primary condition for hospitalization. Irrespective of SBP being primary or nonprimary reason for hospitalization it would be expected that patients receive outpatient
antibiotic prophylaxis post discharge to avoid recurrence of the condition. In general,
concordance with outpatient prescription was observed to be less than desirable which can
eventually influence healthcare utilization patterns, clinical outcomes, and mortality. Though,
association between concordance to medication and utilization patterns was not assessed, the
observed concordance might affect utilization in a general sense.
MELD/MELDNa scores could be comparatively better calculated at complication index as
compared to cirrhosis index. Amongst the three complications, MELD/MELDNa score at
complication index was calculated for nearly all the patients with SBP. HE had the least

102

number of patients for whom the score could be calculated. A window of 3-month pre/post
complication index was used to identify test values used to calculate MELD/MELDNa
scores. Though such a broad window was used, the severity scores could only be calculated
for ≤ 90% for the complication samples (except SBP). This is less than desirable as MELD/
MELDNa are used as a severity measure to prioritize transplant patients. The absence of lab
values used to calculate MELD/MELDNa at complication index can be explained by similar
reasons discussed earlier for MELD/MELDNa scores at cirrhosis index. The observed
concordance to MELD/MELDNa was significantly better than the prescription patterns.
Higher concordance to MELD/MELDNa might have been observed as severity
documentation gives an idea to the physician about the clinical condition/progression of a
patient and is more information-gathering than interventional; whereas, the treatment
modality used might vary based on the patient and the physician judgement. This study
analyzed outpatient prescribing patterns, thus we might have observed lower rates of
concordance as compared to MELD/MELDNa documentation (where a broad inclusion
window was used for the score calculation).
Measures for weight and appointments with gastroenterology were included as measures of
quality care based on good clinical practice, as opposed to specific guideline
recommendations. Weight loss can be due to multiple reasons, and is common symptom of
cirrhosis progression. In addition, weight gain (due to fluid accumulation) can be used as a
surrogate measure for monitoring the status of ascites. Of all the cirrhosis-specific officebased outpatient visits, weight was recorded in 79.69% of total visits. Gastroenterologists are
specialists in cirrhosis-related care and thus it is important that patients are seen by such
specialists to receive best care for management of the condition. Eighty-three percent of
patients with cirrhosis were seen by a gastroenterologist for at least one of the follow-up
office-based outpatient visit recorded in the EMR. For the remaining 17% who did not have a
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record of follow-up visit with gastroenterologist, reasons for no follow-up could not be
assessed due to the nature of the study. Also, depending on the severity of the patient, the
patient might have been referred to an inpatient setting, this again was not confirmed as a part
of the analysis.
In patients with ascites with low ascitic fluid protein, along with impaired renal function or
liver failure, AASLD27 and Kanwal et al37 recommend long-term use of norfloxacin or
trimethoprim/sulfamethoxazole as a primary prophylactic measure to reduce bacterial
infection and mortality. In this study, 33 patients were identified as eligible for this therapy,
of these only 22 (60.61%) received it within 30-days of outpatient visit. Eligible patients
were identified based on diagnosis of ascites at index and the necessary lab values. However,
Child-Pugh score could not be included in the decision process as there was no information
available in the EMR for grade of hepatic encephalopathy, which is necessary to calculate the
score. This study found comparatively better rates of concordance with this quality parameter
as compared to those by Kanwal et al44 (22.2%) and Ghaoui et al40,42 (33.3%) but lower than
those by Thevenot et al46 (72.3%) and Le et al45 Primary prophylaxis is recommended by
AASLD as a measure to reduce risk of SBP and mortality.27
Logistic regression models assessing factors associated with concordance with guidelines had
limited predictability. BMI and physician type, for both ascites and HE model were the only
variables that were associated with concordance with recommended therapy for ascites and
HE. Among the different studies that assessed quality of care in ascites, HE and SBP, the
study by Kanwal et al44 was the only one which studied association of patient- and physicianfactors associated with guideline/QI concordance. The study assessed factors associated with
concordance with eight different quality indicators, whereas this study looked at association
of these factors only with one quality parameter (i.e. receiving outpatient therapy for ascites
and HE).
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In our ascites model, overweight patients had significantly lower odds of receiving diuretic
therapy. Though not statistically significant, obese patients also had lower odds of receiving
diuretic therapy. The negative association of being overweight and concordance with diuretic
therapy is a surprising association and is unknown why a higher BMI would impact diuretic
prescription. Physicians categorized as ‘others’ had significantly lower odds to prescribe
diuretic therapy as compared to primary care physicians. This would be expected as their
knowledge pertaining to ascites care would be anticipated to be more limited than a primary
care physician or gastroenterology specialist. Surprisingly, though not significantly
associated, gastroenterologists were less likely to prescribe diuretic therapy as compared to
primary care physicians.
The logistic model for HE showed that obese patients and physicians categorized as ‘others’
were significantly less likely to receive and prescribe lactulose or lactulose and rifaximin,
respectively. The association between obesity and lower odds of receiving HE therapy may
be attributable to lack of other factors that could not be included in the model due to
availability in the EMR and small sample size. Similar to the ascites model, physicians
categorized as ‘others’ had significantly lower odds to prescribe (adhere to) HE therapy as
compared to primary care physicians. This would be expected as their knowledge pertaining
to HE care would be anticipated to be more limited than a primary care physician or
gastroenterology specialist. Though not significantly associated, gastroenterologists were less
likely to prescribe HE treatment as compared to primary care physicians. In this scenario, it
can also be said that this may be observed as gastroenterologists may have considered a
different treatment modality as these patients may not necessarily have new-onset hepatic
encephalopathy, or have MHE/CHE and thus have other care needs.

105

Limitations
Study limitations must be considered when interpreting the results. The study data was
obtained from EMR of an academic-based network of hospitals serving southwestern
Pennsylvania, thus the study results may not be generalizable to the entire US population.
Second, analysis was conducted using EMR data which might have limited quality due to
recorder bias, incomplete data, coding errors. Data quality due to missing data was accounted
for by using complete case analysis, however it might bias some of the results. Third, limited
sample size was obtained for ascites, HE and specifically for SBP. Thus, a multivariable
logistic model could not be developed for SBP. Fourth, in general, both the logistic models
for ascites and HE did not reveal much about potential associations between the predictors
and outcome. This can be attributable to missing variables in the EMR that could have better
explained the outcome. Fifth, ascites, HE and SBP can be managed both on an outpatient and
inpatient basis and the study looked at quality of care on an outpatient basis only. Inpatient
care might have been provided to these patients instead of outpatient care based on clinical
need. This however could not be ascertained and confirmed due to limited access to inpatient
data. Sixth, reasons for observed concordance to care could not be identified and reported due
to lack of access to patient charts. Finally, this study used a cross-sectional assessment of
quality of care and quality care over time could not be assessed which would have provided a
better estimation.

Study implications
The study findings have various implications for provision of quality care in a clinical setting.
Based on study results, there may be opportunities to improve clinical care for patients with
cirrhosis and complications. First, the study described the demographics and clinical
characteristics of the population served by the network of hospitals providing the EMR. The
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study provides a snapshot of the patient demographic and clinical characteristics that are
prevalent in this population. This study used the CirCom score to identify comorbidity
burden in these patients. This scoring can help physicians understand the burden of
comorbidities in the liver cirrhosis population they serve as well as use it as a tool for future
patients. Second, the study found that there was less than desirable concordance with clinical
care guidelines. EMR are rich sources of data that can be used for providing efficient and
quality care. Use of EMR for assessing patient history and providing the necessary care is
important to achieve better outcomes in patients. In our study, we observed that there was
poor documentation of lab values used to calculate the MELDNa score which is an important
indicator of disease severity and indicator of prioritizing liver transplantation. Though, these
values may have been documented on medical charts, it is important that they be documented
in the EMR for understanding the condition of the patient and accordingly provide necessary
care. In general, documentation of patient data in EMR can provide deep insight into
patient’s condition and be used to provide patient-centered care based on evidence or
established quality parameters.
Lastly, evidence-based guidelines/quality parameters are increasingly used to guide patient
care. The study assessed concordance with some of these and found that they might not be
implemented in real-world clinical practice. Study results can be used by physicians to assess
current practice patterns and accordingly modify them to provide more evidence-based care
and eventually achieve better patient outcomes. The study results highlight need for protocol
driven treatment, opportunities for physician education, and promoting coordinated teambased care to ensure delivery of quality care. Such approaches can be used effectively to
create a systematic health system that provides the necessary evidence-based care using a
structured established process.
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Future directions
Based on the study results, less than desirable concordance with quality care parameters was
observed, which may lead to poor quality of care. This study also tried to assess patient- and
physician- factors associated with concordance with quality care but revealed limited results.
Further research can focus on assessing patient- and physician- factors that govern quality
care which did not yield rich results in this study. Our study mainly focused on outpatient
care due to limited access to inpatient records. Further studies can assess concordance with
quality parameters in an inpatient and outpatient setting and identify factors associated with
quality care. Our study did not assess concordance with quality care and impact on outcomes
which can be assessed by future studies. Liver cirrhosis and the associated complications
involve coordinated care due to the complex nature of the disease. Studies using a
prospective design can be used to assess impact of coordinated care on concordance with
quality care and eventually outcomes.

Conclusion
Chronic liver diseases are the 12th leading cause of mortality in the United States.19 Liver
cirrhosis and the associated complications have no cure and are solely based on management
strategies to slow the disease progression and improve survival. Our study looked at
concordance with various quality care parameters and patient-, and physician- factors
associated with concordance with certain parameters. Overall, we conclude that concordance
with quality care was less than desirable. Study results assessing patient- and physicianfactors associated concordance revealed limited information. The study results highlight lack
of concordance with quality parameters and hence thereof improving care standards to
provide quality care.
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